The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis

Hiam Chemaitelly1*, Karima Chaabna1,2, Laith J. Abu-Raddad1,2

1 Infectious Disease Epidemiology Group, Weill Cornell Medical College in Qatar, Cornell University, Qatar Foundation, Education City, Doha, Qatar, 2 Department of Healthcare Policy & Research, Weill Cornell Medical College, Cornell University, New York, New York, United States of America

Abstract

Objective
To characterize hepatitis C virus (HCV) epidemiology in countries of the Fertile Crescent region of the Middle East and North Africa (MENA), namely Iraq, Jordan, Lebanon, Palestine, and Syria.

Methods
We systematically reviewed and synthesized available records of HCV incidence and prevalence following PRISMA guidelines. Meta-analyses were implemented using a DerSimonian-Laird random effects model with inverse weighting to estimate the country-specific HCV prevalence among the various at risk population groups.

Results
We identified eight HCV incidence and 240 HCV prevalence measures in the Fertile Crescent. HCV sero-conversion risk among hemodialysis patients was 9.2% in Jordan and 40.3% in Iraq, and ranged between 0% and 3.5% among other populations in Iraq over different follow-up times. Our meta-analyses estimated HCV prevalence among the general population at 0.2% in Iraq (range: 0–7.2%; 95% CI: 0.1–0.3%), 0.3% in Jordan (range: 0–2.0%; 95% CI: 0.1–0.5%), 0.2% in Lebanon (range: 0–3.4%; 95% CI: 0.1–0.3%), 0.2% in Palestine (range: 0–9.0%; 95% CI: 0.2–0.3%), and 0.4% in Syria (range: 0.3–0.9%; 95% CI: 0.4–0.5%). Among populations at high risk, HCV prevalence was estimated at 19.5% in Iraq (range: 0–67.3%; 95% CI: 14.9–24.5%), 37.0% in Jordan (range: 21–59.5%; 95% CI: 29.3–45.0%), 14.5% in Lebanon (range: 0–52.8%; 95% CI: 5.6–26.5%), and 47.4% in Syria (range: 21.0–75.0%; 95% CI: 32.5–62.5%). Genotypes 4 and 1 appear to be the dominant circulating strains.
Conclusions

HCV prevalence in the population at large appears to be below 1%, lower than that in other MENA sub-regions, and tending towards the lower end of the global range. However, there is evidence for ongoing HCV transmission within medical facilities and among people who inject drugs (PWID). Migration dynamics appear to have played a role in determining the circulating genotypes. HCV prevention efforts should be targeted, and focus on infection control in clinical settings and harm reduction among PWID.

Introduction

Hepatitis C virus (HCV) is a main risk factor for liver cancer and cirrhosis and is estimated to affect 1–3% of the population in most countries globally [1, 2]. The vast majority of HCV transmission is blood-borne and largely preventable [3, 4]. Recent breakthroughs in HCV treatment research suggest promising prospects for treating and containing the infection, and raise hope for an improved quality of life among infected individuals [5].

In few countries of the Middle East and North Africa (MENA) region, namely Egypt and Pakistan, HCV is prevalent at high levels: 14.7% in Egypt [6, 7] and 4.8% in Pakistan [8, 9]. Meanwhile, infection levels remain poorly estimated for most MENA countries including those in the Fertile Crescent (FC). Geographically, for this study, we define the FC subregion of MENA to include Iraq, Jordan, Lebanon, Palestine, and Syria. Since Egypt was covered by a separate systematic review published recently [7], we did not include Egypt as part of our study. FC countries share historical, socio-cultural, and geo-political similarities, and their health care systems are often directly or indirectly interlinked or affected by decades of political turmoil and refugee waves within this territory.

Our study primarily aims at characterizing HCV epidemiology in these countries by 1) systematically reviewing and synthesizing all available published and unpublished records of HCV incidence and prevalence among the different population groups, and 2) estimating the population-level country-specific HCV prevalence by pooling available HCV prevalence measures among the general population in each country. A secondary outcome of our study is an analysis of HCV genotype diversity. This work is conducted under the umbrella of the MENA HCV Epidemiology Synthesis Project; an ongoing effort to characterize HCV epidemiology and inform key public health research, policy, and programming priorities in MENA [7, 10–15].

Materials and Methods

Data sources and search strategy

We systematically reviewed all HCV incidence (Table 1) and prevalence (Tables 2 and 3 and S2 Table) data in FC following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [16]. The PRISMA checklist can be found in S1 Fig. The methodology was adapted from a recently published protocol for a systematic review of HCV incidence and prevalence measures for countries in the Horn of Africa subregion of MENA [10, 17]. Our search criteria can be found in S2 Fig. Briefly, we surveyed PubMed and Embase (up to April 23, 2015), different regional databases (up to November 5–16, 2014), the abstract archives of the International AIDS Society conferences (up to November 16, 2014), and country-level and international organizations’ reports available through the MENA HIV/AIDS
Epidemiology Synthesis Project database (up to April 23, 2015) [18, 19]. We used a broad search criteria with no language restrictions. PubMed and Embase were searched using text terms and MeSH/Emtree terms exploded to cover all subheadings. Our search was restricted to articles published after 1989, the year when HCV was first discovered [20, 21].

Study selection

The search results were imported into a reference manager, Endnote, where duplicate publications were identified and excluded. The titles and abstracts of remaining records were screened for relevance, and full-texts of articles deemed relevant or potentially relevant were retrieved for further screening. The references of all articles and all reviews of literature were also checked to identify additional articles that could have been potentially missed. Any document reporting a measure of HCV incidence and/or prevalence based on primary data was considered for the review (Fig 1). Case reports, case series, editorials, letters to editors, commentaries, studies referring to hepatitis C as non-A non-B hepatitis, and records of HCV among military personnel who were stationed in this region for some time, but are from countries outside the region, were excluded from our review. A secondary independent screening for articles reporting HCV genotype information, irrespective of their inclusion of HCV incidence and/or prevalence measures, was also performed (S3 Fig).

In this work, a “report” refers to a document containing outcome measures of interest, while a “study” refers to all details pertaining to a specific outcome measure. Accordingly, one report could contribute multiple studies, and multiple reports of the same study, after being identified as duplicates, are considered as one study.

Table 1. Studies reporting hepatitis C virus (HCV) incidence in countries of the Fertile Crescent.

| First author, year of publication [citation] | Year of data collection | Study site | Population’s classification based on risk of HCV exposure | Population | Sample size at recruitment | Lost to follow-up | HCV seroconversion risk (relative to total sample size) | Duration of follow-up |
|-----------------------------------------------|-------------------------|------------|----------------------------------------------------------|------------|----------------------------|------------------|------------------------------------------------------|-----------------------|
| Jordan                                        |                         |            |                                                          |            |                            |                  |                                                      |                       |
| Batieha, 07 [39]                              | 2003                    | Dialysis units/ National | High risk population | Hemodialysis patients | 1300            | 9.2%                       | 12 months                              |                       |
| Iraq                                          |                         |            |                                                          |            |                            |                  |                                                      |                       |
| Al-Rubaie, 11 [40]                            | 2009                    | Hospital   | High risk population | Hemodialysis patients | 57             | 0                           | 40.3%                    | 12 months                  |
| Al-Jadiry, 08 [42]                            | 2007                    | Hospital   | Special clinical population | Pediatric patients with acute lymphoblastic leukemia | 123           | 0                           | 3.2%                     | 30 months (median)          |
| Al-Kubaisy, 00 [44]                           |                         | Hospital   | High risk population | Newborns to HCV infected women | 26             | 0                           | 0%                        | 6 months                   |
| Al-Ali, 14 [41]                               | 2006–07                 | Hospital   | Special clinical population | Pediatric cancer patients on chemotherapy | 85            | 22                          | 3.2%                     | 12 months                  |
| Al-Ani, 11 [43]                               | 2007–09                 | Hospital   | Low risk population | Healthy children | 60             | 0                           | 0%                        | 6 months                   |
| Al-Ani, 11 [43]                               | 2007–09                 | Hospital   | Special clinical population | Pediatric patients with leukemia on chemotherapy | 29            | 0                           | 3.5%                     | 6 months                   |
| Al-Ani, 11 [43]                               | 2007–09                 | Hospital   | Special clinical population | Pediatric patients with leukemia who have had their baseline screening prior to chemotherapy | 27            | 0                           | 0%                        | 6 months                   |

doi:10.1371/journal.pone.0135281.t001

Epidemiology Synthesis Project database (up to April 23, 2015) [18, 19]. We used a broad search criteria with no language restrictions. PubMed and Embase were searched using text terms and MeSH/Emtree terms exploded to cover all subheadings. Our search was restricted to articles published after 1989, the year when HCV was first discovered [20, 21].

Study selection

The search results were imported into a reference manager, Endnote, where duplicate publications were identified and excluded. The titles and abstracts of remaining records were screened for relevance, and full-texts of articles deemed relevant or potentially relevant were retrieved for further screening. The references of all articles and all reviews of literature were also checked to identify additional articles that could have been potentially missed. Any document reporting a measure of HCV incidence and/or prevalence based on primary data was considered for the review (Fig 1). Case reports, case series, editorials, letters to editors, commentaries, studies referring to hepatitis C as non-A non-B hepatitis, and records of HCV among military personnel who were stationed in this region for some time, but are from countries outside the region, were excluded from our review. A secondary independent screening for articles reporting HCV genotype information, irrespective of their inclusion of HCV incidence and/or prevalence measures, was also performed (S3 Fig).

In this work, a “report” refers to a document containing outcome measures of interest, while a “study” refers to all details pertaining to a specific outcome measure. Accordingly, one report could contribute multiple studies, and multiple reports of the same study, after being identified as duplicates, are considered as one study.
| First author, year of publication [citation] | Years of data collection | Study site | Study sampling procedure | Population | Sample size* | HCV prev** |
|---------------------------------------------|--------------------------|------------|--------------------------|-------------|--------------|-----------|
| Iraq (n = 36)                               |                          |            |                          |             |              |           |
| Abdul-Aziz, 01 [46]                        | 1999–01                  | Central laboratory | Convenience            | Hemodialysis patients | 95           | 0%        |
| Abdul-Aziz, 01 [46]                        | 1999–01                  | Central laboratory | Convenience            | Thalassemic patients  | 163          | 8%        |
| Abdul-Karim, 11 [149]                      | 2008                     | Hospital     | Convenience             | Patients with bleeding disorders | 243          | 40.3%     |
| Abdullah, 12 [48]                          | 2010                     | Hemodialysis centers | Convenience      | Hemodialysis patients | 236          | 39%        |
| Abdullah, 12 [47]                          | 2005–07                  | Dialysis unit | Convenience             | Hemodialysis patients | 80           | 28.7%     |
| Abed, 10 [150]                             | 2008                     | Thalassemia center | Convenience            | Thalassemic patients | 111          | 46%        |
| Al-Bahadle, 13 [151]                       | 2011                     | Thalassemia center | Convenience            | Thalassemic patients (0–18 years) | 206          | 19.9%      |
| Al-Barzinji, 06 [152]                      | 2004                     | Hospital     | Convenience             | Multi-transfused leukemia patients on chemotherapy (1–12 years) | 88           | 4.5%       |
| Al-Beldawi, 10 [56]                        | 2006                     | Hemophilia center | Convenience            | Hemophilia patients (<20 years) | 200          | 40%        |
| Al-Dulaimi, 12 [49]                        | 2010–11                  | Hospital     | Convenience             | Hemodialysis patients | 84           | 14.3%     |
| Al-Greti, 13 [153]                         | 2011–12                  | Thalassemia center | Convenience            | Thalassemic patients | 100          | 37%        |
| Al-Juboori, 12 [154]                       | 2010–11                  | Thalassemia center | Convenience            | Thalassemic patients (<20 years) | 50           | 10%        |
| Al Kubaisy, 06 [45]                        | 1998                     | Hospital     | SRS                     | Thalassemic patients (2–10 years) | 559          | 67.3%     |
| Al-Marzoqi, 09 [66]                        | 2008                     | Thalassemia center | Convenience            | Thalassemic patients (children) | 50           | 38%        |
| Al-Mashhadani, 07 [50]                     | 2002                     | Hospital     | Convenience             | Hemodialysis patients | 87           | 11.5%     |
| Al-Thwani, 06 [57]                         | 1997–04                  | Blood transplant center | Convenience       | Hemophilia patients | 100          | 25%        |
| Al Wtaify, 00 [155]                        | 1998–99                  | Thalassemia center | Convenience            | Thalassemic patients (children) | 200          | 9.5%       |
| Al-Zamili, 09 [156]                        | 2007–08                  | Hospital     | Convenience             | Thalassemic patients (<20 years) | 325          | 4%         |
| Easa, 09 [157]                             | 2007–08                  | Thalassemia center | Convenience            | Thalassemic patients (5–18 years) | 140          | 26.4%      |
| Fadhil, 12 [158]                           | 2010–11                  | Thalassemia center | Convenience            | Thalassemic patients | 200          | 21%        |
| Hashem, 13 [159]                           | 2011                     | Hereditary blood diseases center | Convenience | Thalassemic patients | 284          | 19%        |
| Hassan, 08 [137]                           | 1996–01                  | Central laboratory | Convenience            | Thalassemic patients | 136          | 16.9%      |
| Khaled, 14 [160]                           | 2012                     | Thalassemia center | Convenience            | Thalassemic patients | 480          | 10.4%      |
| Khalid, 12 [161]                           | 2012                     | Thalassemia center | Convenience            | Thalassemic patients | 200          | 17.5%      |
| Khattab, 08 [51]                           | 2003–05                  | Renal transplant center | Convenience       | Hemodialysis patients | 169          | 7.1%       |
| Khattab, 10 [52]                           | 2003–08                  | Renal transplant center | Convenience            | Hemodialysis patients | 244          | 4.9%       |
| Mnuti, 11 [53]                             | 2008–10                  | Hemodialysis unit | Convenience            | Hemodialysis patients | 100          | 41%        |
| Muhsin, 13 [58]                            | 2011–12                  | Hospital     | SRS                     | Hemophilia patients | 60           | 6.7%       |
| Muhsin, 13 [58]                            | 2011–12                  | Hospital     | SRS                     | Thalassemic patients | 56           | 25%        |
| Mustafa, 10 [162]                          | 2003–04                  | Thalassemia center | Convenience            | Thalassemic patients (<20 years) | 626          | 28.1%      |
| Omer, 11 [163]                             | 2006–08                  | Hospital     | Convenience            | Multi-transfused leukemia patients | 291          | 3.4%       |
| Omer, 11 [164]                             | 2010                     | Thalassemia center | Convenience            | Thalassemic patients | 54           | 7.4%       |
| Raham, 11 [165]                            | 1999–00                  | Thalassemia center | Convenience            | Thalassemic patients | 110          | 26.4%      |
| Ramzi, 10 [54]                             | 2009                     | Dialysis center | Convenience            | Hemodialysis patients | 101          | 26.7%      |
| Saadoon, 12 [64]                           | 2009                     | Blood trans center | Convenience            | Thalassemic patients | 162          | 34.6%      |
| Shihab, 14 [55]                            | 2012–13                  | Hospital     | Convenience            | Hemodialysis patients | 122          | 42.6%      |
| Jordan (n = 7)                             |                          |            |                          |             |              |           |
| Al-Jamal, 09 [166]                         | 2007–08                  | Hospitals   | Convenience            | Hemodialysis patients | 120          | 28%        |
| Al-Sweedan, 11 [68]                        | 2008                     | Thalassemia unit | Convenience            | Thalassemic patients | 122          | 32.8%      |
| Batchou, 11 [167]                          | 2008                     | Hospitals   | Convenience            | Hemodialysis patients | 134          | 47.7%      |
| Batieha, 07 [39]                           | 2003                     | Hemodialysis units | Convenience            | Hemodialysis patients | 1711         | 21%        |

(Continued)
Data extraction and data synthesis

Data from relevant reports were extracted by HC. To check for consistency, 10% of the reports were double extracted by another co-author (KC). The list of extracted information can be found in S1 Table. The extracted data were then synthesized by country and by populations’ risk of acquiring HCV (high, intermediate, and low risk). Our classification of risk was informed by HCV epidemiology literature [2, 22, 23] and a previously published classification [12]. In events where the level of exposure to HCV in certain populations was uncertain, and hence difficult to classify within the three pre-determined levels of risk, we followed a conservative approach that grouped such populations into a distinct risk category. We labeled this category as ‘special clinical populations’ since all of these populations were clinical populations. Details pertaining to the definitions and risk classification of identified populations can be found in S4 Fig.

The quality of HCV incidence and prevalence measures identified through our review was determined by assessing the risk of bias (ROB) for each study using the Cochrane approach.
Table 3. Studies reporting hepatitis C virus (HCV) prevalence among the general population (populations at low risk) in countries of the Fertile Crescent.

| First author, year of publication [citation] | Years of data collection | Study site | Study sampling procedure | Population | Sample size * | HCV prev ** |
|---------------------------------------------|--------------------------|------------|--------------------------|------------|---------------|------------|
| Iraq (n = 45)                                |                          |            |                          |            |               |            |
| Abdul-Aziz, 01 [46]                          | 1999–01                  | Central laboratory | Convenience | Blood donors | 20108 | 0.8%       |
| Abdul-Aziz, 01 [46]                          | 1999–01                  | Central laboratory | Convenience | New employees | 257 | 0.4%       |
| Abdullah, 12 [47]                            | 2005–07                  | Convenience | Blood donors | 100 | 1% |
| Al-ANI, 11 [43]                              | 2007–09                  | Hospital | Convenience | Children | 60 | 0% |
| Al-Azzawi, 06 [171]                          | 2004                     | Primary health centers | Convenience | Pregnant women | 100 | 1% |
| Al-Doori, 06 [172]                           | 2004–05                  | Central laboratory | Convenience | Blood donors | 1978 | 0.4% |
| Al-Dulaimi, 12 [173]                         | 2010–11                  | Central laboratory | SRS | Blood donors | 90 | 0% |
| Al-Greti, 13 [153]                           | 2011–12                  | Convenience | General population | 50 | 4% |
| Al-Hamdani, 12 [174]                         | 2003–04, 06, 08–09       | Hospital | Convenience | New employees | 4162 | 2.6% |
| Ali, 09 [175]                                | 2007–08                  | Blood bank | Convenience | Blood donors | 600 | 1.7% |
| Al-Jebori, 10 [176]                          | 2003–09                  | Central laboratory | Convenience | Mixed general population | 120460 | 0.2% |
| Aljooani, 12 [177]                           | 2005–07                  | Hospital | Convenience | Blood donors | 430 | 2.8% |
| Al-Juboury, 10 [178]                         | 2007–08                  | Blood bank | Convenience | Blood donors | 23336 | 0.5% |
| Al-Kamil, 11 [179]                           | 2006–08                  | Central blood bank | Convenience | Blood donors | 161987 | 0.1% |
| Al-Kubaisy, 02 [102]                         | 2003–04                  | Hospitals & health care centers | SRS | Pregnant women | 3491 | 3.2% |
| Al-Saad, 09 [61]                             | 2008                     | Hospital | Convenience | General population | 100 | 0% |
| Al Wtaify, 00 [155]                          | 1998–99                  | Hospital | SRS | Outpatient hospital attendees (children) | 200 | 0.5% |
| Al-Zamili, 09 [156]                          | 2007–08                  | Hospital | Convenience | Children | 325 | 0% |
| Amin, 12 [180]                               | 2008–09                  | Blood bank | Convenience | Blood donors | 35540 | 0.1% |
| Ataallah, 11 [181]                           | 2006–09                  | National blood trans center | Convenience | Blood donors | 495648 | 0.3% |
| Chaid, 09 [182]                              | 2003–04                  | National blood trans center | Convenience | Blood donors | 1000 | 1% |
| Chironna, 03 [105]                           | 2008                     | Refugee camp | Convenience | Refugees | 637 | 0.1% |
| Fadhil, 12 [158]                             | 2010–11                  | Hospital | Convenience | Outpatient hospital attendees | 50 | 0% |
| Fawzi, 11 [183]                              | 2010                     | Hospital & health centers | Convenience | Pregnant women | 520 | 1.1% |
| Hamim, 12 [184]                              | 2006–10                  | Main blood trans center | Convenience | Outpatient hospital attendees | 4886 | 0.9% |
| Hamim, 12 [185]                              | 2008–09                  | Blood trans centers | Convenience | Blood donors | 871973 | 0.4% |
| Hassan, 08 [137]                             | 1996–01                  | Central laboratory | Convenience | Blood donors | 42140 | 0.1% |
| Hussain, 08 [186]                            | 2004–05                  | Hospital | Convenience | General population | 108 | 0% |
| Hussein, 10 [187]                            | 2006–07                  | Central blood bank | Convenience | Blood donors | 31574 | 0.1% |
| Hussein, 10 [188]                            | 2008–09                  | Convenience | Blood donors | 117 | 0.8% |
| Jassim, 11 [189]                             | 2006–10                  | Central blood bank | Convenience | Blood donors | 170 | 0% |
| Khalid, 12 [161]                             | 2007–08                  | Central blood bank | Convenience | Blood donors | 100 | 2% |
| Naji, 13 [190]                               | 2011–12                  | Central laboratory | Convenience | Newly married individuals | 200 | 1.5% |
| Noaman, 12 [63]                              | 2009–10                  | Blood bank | Convenience | Blood donors | 93 | 1.1% |
| Obied, 14 [100]                              | 2012–13                  | Central blood bank | Convenience | Blood donors | 5179 | 0.4% |
| Omer, 11 [163]                               | 2006–08                  | Hospital | Convenience | General population | 350 | 0.3% |
| Richter, 14 [191]                            | 2011                     | Community | Convenience | First generation immigrants | 290 | 0.3% |

(Continued)
| First author, year of publication [citation] | Years of data collection | Study site | Study sampling procedure | Population | Sample size* | HCV prev** |
|---------------------------------------------|--------------------------|------------|--------------------------|------------|-------------|------------|
| Saadoon, 08 [192]                           | 2007                     | Hospitals  | Convenience              | Pregnant women | 875         | 5.1%       |
| Saadoon, 12 [64]                            |                          | Blood bank | Convenience              | Blood donors | 1128        | 0.6%       |
| Salih, 07 [193]                             | 2007                     | Hospital   | Convenience              | Blood donors | 95          | 2.1%       |
| Salman, 07 [194]                            | 2006–07                  | Antenatal clinics | Convenience           | Pregnant women | 60          | 0%         |
| Tarky, 13 [59]                              | 2005–06                  | Households | SRS                      | General population | 9610        | 0.4%       |
| Tawfeeq, 13 [101]                           | 2011–12                  | Blood bank | Convenience              | Blood donors | 15560       | 0.3%       |
| Tofik, 06 [195]                             |                          | Hospital   | Convenience              | Outpatient clinic attendees | 100         | 0%         |
| Tofik, 06 [195]                             |                          |            |                          | Blood donors | 200         | 0.5%       |
| **Jordan (n = 5)**                          |                          |            |                          | Blood donors |             |            |
| Al Abbadi, 14 [196]                         | 2009–11                  | Blood bank | Convenience              | Blood donors | 94270       | 0.1%       |
| Al-Gani, 11 [197]                           | 2006–09                  | Blood bank | Convenience              | Blood donors | 8190        | 0.9%       |
| Hamoudi, 13 [112]                           |                          | Health centers | SRS                   | Health centers’ attendees | 706         | 0.4%       |
| Jbara, 06 [198]                             | 2003–05                  | Blood bank | Convenience              | Blood donors | 8750        | 0.8%       |
| Rashdan, 08 [103]                           | 2004–06                  | Blood bank | Convenience              | Blood donors | 14236       | 0.2%       |
| **Lebanon (n = 13)**                        |                          |            |                          | Blood donors |             |            |
| Araj, 95 [77]                               |                          | Laboratories (nation-wide) | SRS                | General population (Lebanese) | 2879        | 0.6%       |
| Baddoura, 02 [84]                           |                          | Laboratories (nation-wide) | Convenience        | General population (Lebanese) | 103         | 2.9%       |
| Irani-Hakime, 01 [199]                      | 1999                     | Blood bank | Convenience              | Blood donors | 600         | 0.2%       |
| Irani-Hakime, 06 [78]                       | 1997–03                  | Blood bank | Convenience              | Blood donors | 16084       | 0.4%       |
| Nabulsi, 97 [80]                            | 1993–95                  | Antenatal clinics | Convenience           | Pregnant women | 558         | 0%         |
| Naman, 96 [73]                              |                          |            |                          | Blood donors | 7771        | 0.4%       |
| Ramia, 03 [76]                              |                          | Hospital   | SRS                      | Blood donors | 500         | 0.2%       |
| Ramia, 05 [81]                              | 2002–03                  | Blood bank | SRS                      | Blood donors | 56          | 0%         |
| Salem, 03 [82]                              |                          | Hospital   | SRS                      | Outpatient hospital attendees | 70          | 0%         |
| Salem, 03 [82]                              |                          | Hospital   | SRS                      | Blood donors | 150         | 0%         |
| Tamim, 01 [83]                              | 1998–00                  | Blood bank | Convenience              | Blood donors (Lebanese) | 5027        | 0.3%       |
| Tamim, 01 [83]                              | 1998–00                  | Blood bank | Convenience              | Blood donors (non-Lebanese) | 88          | 3.4%       |
| **Palestine (n = 11)**                      |                          |            |                          | Blood donors |             |            |
| PHIC, 14 [33]                               | 2013                     | Blood banks (hospitals) |            | Blood donors | 19571       | 0.2%       |
| PHIC, 14 [33]                               | 2013                     | National blood bank |            | Blood donors | 9643        | 0.3%       |
| MENA HIV ESP, 11 [18, 32]                   | 2011                     |            |                          | Blood donors | 63477       | 0.2%       |
| PHIC, 10 [34]                               | 2009                     | Blood banks (hospitals) |            | Blood donors | 48001       | 0.2%       |
| PHIC, 08 [35]                               | 2007                     | Blood banks (hospitals) |            | Blood donors | 49105       | 0.3%       |
| PHIC, 07 [36]                               | 2006                     |            |                          | Blood donors | 53151       | 0.2%       |
| PHIC, 06 [37]                               | 2005                     | Blood bank |            | Blood donors | 45029       | 0.2%       |
| PHIC, 04 [38]                               | 2003                     | Blood bank |            | Blood donors | 44990       | 0.3%       |
| Novack, 07 [91]                             | 1999–02                  | Blood bank | Convenience              | Blood donors | 2784        | 3.9%       |
| Shemer-Avni, 98 [90]                        |                          | Blood bank | Convenience              | Blood donors | 1509        | 2.2%       |

(Continued)
[24], and by evaluating the precision of the reported measures. A description of the quality assessment criteria and studies’ ROB appraisal can be found in **S5 Fig.**

**Quantitative analysis**

For each country, HCV antibody and RNA prevalence data in studies comprising at least 50 participants were stratified by population risk and summarized using reported ranges (Tables 2 and 3, and S2 and S3 Tables). Meta-analyses of HCV prevalence measures were conducted, for each country, for the various populations at risk whenever at least five HCV measures were available. Studies comprising a minimum of 25 participants were considered eligible for inclusion in the meta-analysis. HCV prevalence for the total sample was replaced with stratified measures whenever the sample size requirement was fulfilled at the level of each stratum. For each study, one final stratification was considered based on a pre-defined sequential order that prioritizes nationality followed by population, sex, year, region, and age.

The variance of the prevalence measures was stabilized using the Freeman-Tukey type arcsine square-root transformation [25]. Estimates for HCV prevalence were weighed using the inverse variance method and then pooled using a DerSimonian-Laird random effects model [26]. This model assumes a normal distribution of true effect sizes across studies, and therefore accounts for the sampling variation as well as the heterogeneity in effect size [27]. Heterogeneity measures were also calculated (Table 4) [27, 28].

For each country, we calculated the frequency of occurrence of each genotype relative to all identified genotypes (Table 5). Here, individuals testing positive for multiple genotypes contributed separately to the quantification of each of the identified genotypes. Shannon Diversity Index [29] was applied to the resulting distributions to assess the diversity of genotypes across...
245 citations identified through PubMed (n=92) and Embase (n=153)

88 duplicates removed

157 unique citations identified and titles/abstracts screened

65 excluded after abstract screening

146 excluded after abstract screening

166 unique reports retrieved for full-text searching (PubMed and Embase= 92, regional databases=74)

51 reports excluded*

115 eligible reports

21 additional HCV prevalence measures identified through the Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project database

20 additional reports identified through references and reviews

135 eligible reports + 21 additional HCV prevalence measures included in the systematic review

8 HCV incidence and 240 HCV prevalence measures

*Reasons for exclusion:
- Eligibility criteria not met (n=6)
- Full-text did not include data on relevant indicators (n=12)
- Full-text could not be retrieved and abstract does not have data on relevant outcomes (n=6)
- Abstract and full-text could not be retrieved (n=11)
- Conference abstract did not include data on relevant indicators (n=2)
- Duplicate data (n=14)

Fig 1. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) incidence and prevalence in the Fertile Crescent countries, adapted from the PRISMA 2009 guidelines [16].

doi:10.1371/journal.pone.0135281.g001
Table 4. Pooled mean estimates for hepatitis C virus (HCV) prevalence stratified by populations’ risk of infection across countries of the Fertile Crescent.

| Country          | Studies | Samples | Prevalence | Effect size | Heterogeneity measures |
|------------------|---------|---------|------------|-------------|------------------------|
|                  | Total N | Total N | Range (%)  | Mean (%)    | 95% CI                 | Q (p-value)* | \(\tau^2\) | \(I^2\) (confidence limits) | Prediction interval (%)\(^\dagger\) |
| **Iraq**         |         |         |            |             |                        |             |          |                             |                              |
| General population | 99      | 1859563 | 0.0–7.2    | 0.2 | 0.1–0.3 | 2355.9 (p<0.0001) | 0.0014 | 95.8% (95.3–96.3%) | 0.0–0.8                     |
| Populations at high risk | 58      | 6707   | 0.0–67.3   | 19.5 | 14.9–24.5 | 1345.8 (p<0.0001) | 0.1982 | 95.8% (95.1–96.4%) | 0.0–62.8                    |
| Populations at intermediate risk | 28      | 8398   | 0.0–35.1   | 1.5 | 0.7–2.5 | 205.2 (p<0.0001) | 0.0227 | 86.8% (82.1–90.3%) | 0.0–8.2                     |
| Special clinical populations | 45      | 18845  | 0.0–76.2   | 5.0 | 3.4–6.9 | 1146.5 (p<0.0001) | 0.0631 | 96.2% (95.5–96.7%) | 0.0–22.1                    |
| **Jordan**       |         |         |            |             |                        |             |          |                             |                              |
| General population | 12      | 126152 | 0.0–2.0    | 0.3 | 0.1–0.5 | 170.7 (p<0.0001) | 0.0016 | 93.6% (90.5–96.6%) | 0.0–1.1                     |
| Populations at high risk | 12      | 2888   | 21.0–59.5  | 37.0 | 29.3–45.0 | 137.8 (p<0.0001) | 0.07 | 92.0% (87.9–94.7%) | 11.1–67.7                    |
| Populations at intermediate risk | 1      | 152    | 0.65       |     |          |             |          |                             |                              |
| Special clinical populations | 1      | 143    | 40.5       |     |          |             |          |                             |                              |
| Mixed populations | 1       | 426    | 4.5        |     |          |             |          |                             |                              |
| **Lebanon**      |         |         |            |             |                        |             |          |                             |                              |
| General population | 16      | 38059  | 0.0–3.4    | 0.2 | 0.1–0.3 | 38.2 (p<0.0008) | 0.0008 | 60.8% (32.3–77.3%) | 0.0–0.7                     |
| Populations at high risk | 10      | 1309   | 0.0–52.8   | 14.5 | 5.6–26.5 | 223 (p<0.0001) | 0.2011 | 96.0% (94.2–97.2%) | 0.0–66.0                    |
| Populations at intermediate risk | 7      | 1050   | 0.0–7.7    | 1.2 | 0.1–3.3 | 24.9 (p<0.0003) | 0.0224 | 76.0% (49.3–88.6%) | 0.0–10.7                    |
| Special clinical populations | 4      | 312    | 0.0–19.6   |     |          |             |          |                             |                              |
| **Palestine**    |         |         |            |             |                        |             |          |                             |                              |
| General population | 53      | 337384 | 0.0–9.0    | 0.2 | 0.2–0.3 | 637.8 (p<0.0001) | 0.0019 | 91.8% (90.1–93.3%) | 0.0–0.9                     |
| Populations at high risk | 4      | 584    | 6.8–45.2   |     |          |             |          |                             |                              |
| Special clinical populations | 0      |         |            |     |          |             |          |                             |                              |
| Mixed populations | 12      | 53363  | 0.3–4.9    |     |          |             |          |                             |                              |
| **Syria**        |         |         |            |             |                        |             |          |                             |                              |
| General population | 17      | 1114550| 0.3–0.9    | 0.4 | 0.4–0.5 | 216.8 (p<0.0001) | 0.0002 | 92.6% (89.7–94.7%) | 0.3–0.7                     |
| Populations at high risk | 8      | 1279   | 21.0–75.0  | 47.4 | 32.5–62.5 | 190.6 (p<0.0001) | 0.1779 | 96.3% (94.5–97.6%) | 3.8–93.8                    |
| Populations at intermediate risk | 4      | 725    | 2.0–5.8    |     |          |             |          |                             |                              |
| Special clinical populations | 2      | 218    | 1.0–48.0   |     |          |             |          |                             |                              |

All countries

| Studies | Samples | Prevalence | Effect size | Heterogeneity measures |
|---------|---------|------------|-------------|------------------------|
| General population | 197      | 3475708  | 0.0–9.0    | 0.2 | 0.2–0.3 | 4497.5 (p<0.0001) | 0.0013 | 95.6% (95.3–96.0%) | 0.0–0.8                     |

(Continued)
Table 4. (Continued)

| Studies | Samples | Prevalence | Effect size | Heterogeneity measures |
|---------|---------|------------|-------------|------------------------|
|         | Total N | Total N | Range (%) | Mean (%) | 95% CI | Q (p-value)* | \( \tau^2 \) ** | \( I^2 \) (confidence limits)† | Prediction interval (%)‡ |
| Populations at high risk | 92 | 12767 | 0.0–75.0 | 23.6 | 19.8–27.5 | 2273.6 (p<0.0001) | 0.1762 | 96.0% (95.5–96.4%) | 0.3–64.5 |
| Populations at intermediate risk | 40 | 10325 | 0.0–35.2 | 1.5 | 0.9–2.3 | 243.5 (p<0.0001) | 0.0208 | 84.0% (79.0–87.8%) | 0.0–7.7 |
| Special clinical populations | 52 | 19518 | 0.0–76.2 | 5.4 | 3.7–7.4 | 1377.9 (p<0.0001) | 0.0729 | 96.3% (95.7–96.8%) | 0.0–24.4 |
| Mixed populations | 13 | 53789 | 0.3–4.9 | | | | | | |

*Q: the Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
**\( \tau^2 \): the estimated between-study variance in the double arcsine transformed proportions of the true effect sizes. The back-transformed \( \tau^2 \) was not calculated as the methodology to do so is not currently available.
†\( I^2 \): a measure assessing the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
‡Prediction interval: estimates the 95% interval in which the true effect size in a new HCV study will lie.

doi:10.1371/journal.pone.0135281.t004

countries, with a higher score indicating more diversity (Table 5). The country-specific distributions of HCV genotypes among HCV RNA positive individuals were also described (S6 Fig).

Analyses were performed using SPSS 22.0 [30] and R 3.1.2. [31].

Results

Search results

Fig 1 describes the process of study selection based on PRISMA guidelines [16]. We identified a total of 465 citations (92 through PubMed, 153 through Embase, and 220 through regional databases). A total of 166 records were identified as relevant or potentially relevant after removing duplicates and screening the titles and abstracts of remaining records. Out of these, 115 records were eligible for inclusion in the systematic review during the full-text screening stage. Twenty additional records were identified through screening the bibliographies of studies and reviews. Twenty one HCV prevalence measures from country-level data were also identified through the MENA HIV/AIDS Epidemiology Synthesis Project database [18, 32–38]. To sum, a total of 135 eligible reports and 21 HCV prevalence measures from county-level data

Table 5. Frequency, distribution and Shannon Diversity Index of identified hepatitis C virus (HCV) genotypes across countries of the Fertile Crescent.

| Country | Iraq n (%) | Jordan n (%) | Lebanon n (%) | Palestine n (%) | Syria n (%) |
|---------|------------|--------------|--------------|----------------|------------|
| Genotype 1 | 212 (33.2%) | 30 (42.3%) | 134 (39.9%) | 38 (28.6%) | 199 (29.5%) |
| Genotype 2 | 3 (0.5%) | 53 (15.8%) | 1 (0.8%) | 5 (0.7%) | 11 (1.6%) |
| Genotype 3 | 24 (3.8%) | 40 (11.9%) | 2 (1.5%) | 11 (1.6%) | |
| Genotype 4 | 399 (62.5%) | 41 (57.7%) | 108 (32.1%) | 92 (69.2%) | 392 (58.2%) |
| Genotype 5 | 1 (0.3%) | 67 (9.9%) | |
| Genotype 6 | |
| Genotype 7 | |
| Shannon Diversity Index (H) | 0.81 | 0.68 | 1.29 | 0.71 | 1.00 |
| Index relative to total possible diversity | 41.5% | 35.0% | 66.5% | 36.6% | 51.8% |

doi:10.1371/journal.pone.0135281.t005
were included in the systematic review. These yielded 8 HCV incidence/sero-conversion and 240 HCV prevalence measures.

All 465 citations identified through our search underwent an independent secondary screening for HCV genotype studies (S3 Fig). A total of 163 records were identified as relevant or potentially relevant after removing duplicates and screening the titles and abstracts of remaining records. Out of these, 29 records were eligible for inclusion in this secondary systematic review during the full-text screening stage yielding 47 HCV genotype study measures.

HCV incidence overview

Out of all countries being analyzed (Iraq, Jordan, Lebanon, Palestine, and Syria), data on HCV incidence was only available for Iraq and Jordan. There were no studies reporting strictly HCV incidence rate per person-year. All eight identified incidence measures were based on risk of sero-conversion over a specified time frame (Table 1). One study conducted across all dialysis units in Jordan reported a sero-conversion risk of 9.2% over one year [39]. The rest of the studies were conducted in Iraq. In one study among hemodialysis patients, a sero-conversion risk of 40.3% over one year was reported [40]. Lower HCV sero-conversion risks ranging from 0–3.5% were observed among pediatric cancer patients [41–43]. A study among newborns to HCV infected mothers reported 100% clearance of maternal antibodies by six months of age [44].

HCV prevalence overview

We present here an overview of HCV prevalence studies identified in Iraq, Jordan, Lebanon, Palestine, and Syria. For the purpose of this analysis, we excluded HCV prevalence studies that were based on samples of less than 50 participants (37 studies). Accordingly, we report on a total of 203 HCV prevalence studies including 125 studies from Iraq, 15 from Jordan, 27 from Lebanon, 17 from Palestine, and 19 from Syria.

**Iraq.** Among populations at high risk (Table 2), high HCV prevalence levels ranging from 4% to 67.3% were reported among thalassemic patients, with the highest prevalence being observed among the 2 to 10 year-olds [45]. High HCV prevalence levels were also found among hemodialysis patients (range: 0–42.6%) [46–55] and hemophilia patients (range: 6.7–40%) [56–58].

For the general population (Table 3), HCV prevalence varied between 0% and 5.1%, and ranged between 0% and 2.8% among blood donors, 0% and 5.1% among pregnant women, and was 0.4% in a national household-based survey [59] and overall less than 1% among other general population groups.

Among populations at intermediate risk (S2 Table), HCV prevalence ranged from 0% to 3.3% among health care workers [46, 50, 60–64], and was higher among dental providers (9.1%) [65], hospitalized patients (14%) [66], and type I diabetes mellitus patients (35.1%) [67]. HCV prevalence also varied widely among special clinical populations ranging from 0% among patients with malignancies or liver-related problems to 71.9% among acute viral hepatitis patients (S2 Table).

**Jordan.** Among populations at high risk (Table 2), high HCV prevalence levels ranging from 21% to 49.8% were observed among hemodialysis patients. A prevalence of 32.8% was also observed among thalassemic patients [68].

For the general population (Table 3), low HCV prevalence levels of less than 1% were observed among blood donors and people attending health centers (range: 0.1–0.9%). Among populations at intermediate risk and special clinical populations (S2 Table), low HCV
prevalence of 0.6% was reported among health care workers [69] and high prevalence of 40.5% was reported among patients with hemolytic anemia [70].

**Lebanon.** Among populations at high risk (Table 2), high HCV prevalence of 52.8% was reported among PWID [71]. Overall high HCV prevalence was also reported among other populations at high risk (Table 2) such as hemodialysis patients (16% [72] and 27% [73]), thalassemia patients (0% [74] and 14% [75]), and multi-transfused cancer patients (4.6% [76]).

For the general population (Table 3), HCV prevalence was measured at less than 0.6% among Lebanese nationals [73, 76–84] and at about 3% among non-Lebanese nationals residing in Lebanon [83, 84].

Rather low HCV prevalence was observed among populations at intermediate risk ranging from 0% among female sex workers and men who have sex with men to 7.7% among HIV patients infected apparently via the sexual route (S2 Table). Among special clinical populations (S2 Table), HCV prevalence was 19.6% [85] among hepatocellular carcinoma patients and 0% [82, 86] among patients with other malignancies.

**Palestine.** Among populations at high risk (Table 2), HCV prevalence was measured at 27.4% among hemodialysis patients in the West Bank [87], and at 17.9% among hemodialysis patients in the Gaza strip [88]. A prevalence of 45.2% was reported among PWID in East Jerusalem [89].

For the general population (Table 3), HCV prevalence among blood donors from different parts of Palestine ranged between 0.2% and 0.3% [18, 32–38]. In older studies, all of which were in the Gaza strip, HCV prevalence was reported at 2.2% and 3.9% among blood donors [90, 91] and at 9% among outpatient hospital attendees [90].

**Syria.** Among populations at high risk (Table 2), high HCV prevalence ranging from 48.9% to 75% was reported among hemodialysis patients [92–94]. Meanwhile, HCV prevalence among drug users (injecting and non-injecting) and among hemophilia patients was measured at 21% [95] and 20.5% [96], respectively.

For the general population (Table 3), HCV prevalence ranged between 0.3% and 0.9% among blood donors. Among populations at intermediate risk (S2 Table), HCV prevalence ranged between 2% among female sex workers [97] and up to 3.8% among health care workers [98]. The only study among special clinical populations (S2 Table) was among acute viral hepatitis patients and reported a prevalence of 1.0% [99].

**Overall HCV prevalence ranges and medians.** For all countries, HCV prevalence ranged from 0–75% among populations at high risk with a median of 25.0%, from 0–9% among populations at low risk with a median of 0.4%, from 0–35.1% among populations at intermediate risk with a median of 1.2%, and from 0–71.9% among special clinical populations with a median of 3.4%.

**Pooled mean HCV prevalence estimates**

Our pooled country-specific estimates for the national population-level HCV prevalence, based on pooling the general population measures, were: 0.2% (95% CI: 0.1–0.3%) in Iraq, 0.3% (95% CI: 0.1–0.5%) in Jordan, 0.2% (95% CI: 0.1–0.3%) in Lebanon, 0.2% (95% CI: 0.2–0.3%) in Palestine, 0.4% (95% CI: 0.4–0.5%) in Syria, and 0.2% (95% CI: 0.2–0.3%) in FC countries as a whole (Table 4). The prediction interval for each of these pooled means, that is the estimated 95% interval range for the true effect size (HCV prevalence) across studies, also rarely exceeded 1% (Table 4). The forest plots of the country-specific meta-analyses can be found in S7–S9 Figs.

High pooled HCV prevalence levels were estimated for populations at high risk: 19.5% (95% CI: 14.9–24.5%) in Iraq, 37.0% (95% CI: 29.3–45.0%) in Jordan, 14.5% (95% CI: 5.6–26.5%) in
Lebanon, 47.4% (95% CI: 32.5–62.5%) in Syria, and 23.6% (95% CI: 19.8–27.5%) in FC countries as a whole (Table 4). The prediction intervals for these measures were also wide across countries (Table 4).

For populations at intermediate risk, the pooled HCV prevalence was 1.5% (95% CI: 0.7–2.5%) in Iraq, 1.2% (95% CI: 0.1–3.3%) in Lebanon, and 1.5% (95% CI: 0.9–2.3%) in FC countries as a whole (Table 4). For special clinical populations, the pooled HCV prevalence was 5.0% (95% CI: 3.4–6.9%) in Iraq and 5.4% (95% CI: 3.7–7.4%) in FC countries as a whole (Table 4). The prediction intervals for these measures were also wide across countries (Table 4).

There was significant evidence for heterogeneity in effect size in all meta-analyses, the p-value was always <0.001 (Table 4). Most of the variation in all meta-analyses was attributed to variation in effect size across studies rather than chance (I² >60%; Table 4).

HCV RNA prevalence

Our search identified a total of 34 HCV RNA measures (S3 Table). Generally high HCV RNA prevalence was found among HCV antibody positive individuals at high risk across all countries ranging from 26.1% among hemodialysis patients to 88% among thalassemia patients. HCV RNA prevalence was also substantial among HCV antibody negative individuals at high risk ranging from 3.5% among hemodialysis patients to 16.7% among thalassemic children.

For the general population (S3 Table), the prevalence of HCV RNA among HCV antibody positive individuals in Iraq and Palestine hovered around 65% in different samples of blood donors [90, 100, 101], pregnant women [102], and outpatients [90], but was at 89.7% among blood donors in Jordan [103].

HCV genotypes

Information on HCV genotypes was available in 47 studies including a total of 1749 HCV RNA positive individuals (Table 5 and S6 Fig).

In Iraq, the majority of participants were infected by a single strain, only 11.3% had multiple genotypes isolated from their plasma (S6A Fig) [45, 48, 101, 102, 104–110]. The distribution of HCV genotypes showed a high prevalence for genotype 4 (62.5%) and genotype 1 (33.2%) followed by genotype 3 (3.8%) and genotype 2 (0.5%) (Table 5). Subtypes 1a and 1b were isolated, respectively, from 33.2% and 66.8% of infected persons with genotype 1 (where subtype information was available). About two-third of the infections among populations at high risk and slightly more than half of those among general populations were attributed to genotype 4.

All HCV RNA positive individuals in Jordan were infected by a single strain (S6B Fig), with 57.7% carrying genotype 4 and 42.3% carrying genotype 1 (Table 5) [68, 103, 111, 112]. Subtypes 1a and 1b were isolated, respectively, from 54.5% and 45.5% of infected persons with genotype 1. The majority of genotype 1 samples were among hemodialysis and thalassemia patients, while samples with genotype 4 were equally distributed between populations at high risk and the general population.

In Lebanon, over 90% of participants were infected by a single strain (S6C Fig) [71, 72, 75, 76, 113–117]. The distribution of genotypes indicated genotype 1 as the most common (39.9%), followed by genotype 4 (32.1%), genotype 2 (15.8%), genotype 3 (11.9%) and genotype 5 (0.3%) (Table 5). Studies reporting subtype information for genotype 1 showed an equal distribution of subtypes 1a and 1b. About half of genotype 3 infections (47.5%) were collected among PWID; and an additional third were collected among hemodialysis and thalassemia patients. Genotype 3 was also identified in a prison setting [113]. Genotype 5 was reported in only one study among a sample of patients with symptomatic liver disease [116].
All HCV genotype studies in Palestine were conducted in the Gaza strip [90, 118]. Almost all infections were single stranded (S6D Fig). Genotype 4 was the most common (69.2%), followed by genotype 1 (28.6%), genotype 3 (1.5%) and genotype 2 (0.8%) (Table 5). Subtypes 1a and 1b constituted, respectively, 69.0% and 31.0% of genotype 1 cases.

The distribution of HCV genotypes in Syria (S6E Fig) revealed genotype 4 as the most common (58.2%) followed by genotype 1 (29.5%), genotype 5 (9.9%), genotype 3 (1.6%) and genotype 2 (0.7%) (Table 5) [92, 119, 120]. Subtypes 1a and 1b were isolated, respectively, from 44.4% and 55.6% of infected persons with genotype 1.

The largest possible value for the Shannon Diversity Index, assuming equal distribution of the seven known HCV genotypes [121], is 1.95 [29]. Lebanon scored highest on this index (H = 1.29 out of 1.95 or 66.5%) indicating high diversity in the types and frequency of isolated genotypes (Table 5). The next most diverse genotype distributions were found in Syria (H = 1.00 out of 1.95 or 51.8%), and Iraq (H = 0.81 out of 1.95 or 41.5%), while the least diversity was observed in Palestine, more specifically in the Gaza strip (H = 0.71 out of 1.95 or 36.6%), and Jordan (H = 0.68 out of 1.95 or 35.0%).

Risk factors for HCV infection

Few studies (n = 5) investigated possible risk factors for HCV infection using multivariable logistic regression analyses. Common reported risk factors among hemodialysis patients included duration of dialysis and number of blood units transfused [54, 94]. Among individuals presenting to laboratory units for diverse testing in Lebanon, hemodialysis was the main risk factor for HCV infection [84]. Meanwhile, maternal age and number of previous miscarriages were identified as the main risk factors for HCV infection among pregnant women in Iraq [102]. Among patients suspected of having acute viral hepatitis, blood transfusion, tattooing, and cupping were identified as risk factors for HCV infection in a study in Iraq [122].

Quality assessment of HCV incidence and prevalence measures

The results of the quality assessment conducted for the HCV incidence and prevalence measures are summarized in S4 Table. The study-specific quality assessment for each of these measures is found in S5–S8 Tables.

The majority of HCV incidence studies involved samples of less than 100 patients, and thus were classified as having low precision. All studies were based on convenience samples selected from clinical facilities and were characterized by a high response rate. The type and generation of the biological assays used to ascertain infection were specified in almost all studies, with more than half relying on the more recent, sensitive and specific 3rd and 4th generation ELISA tests.

The majority of HCV prevalence measures had high precision (81.3%). The ROB assessment was possible for 184 HCV prevalence measures, while 19 measures were judged to be of unknown quality as limited description of the samples was available and were excluded from further analyses. However, all studies with unknown ROB were based on testing among blood donors reported by ministries of health and blood banks. For the vast majority of measures (98.4%), HCV ascertainment was based on biological assays. Information about the generation of the used assay was missing for more than half of the studies. Among studies with information on the assay’s generation, 85.2% reported the use of the more sensitive and specific 3rd and 4th generation assays. Most of the studies were drawn using convenience sampling. Half of the studies had low ROB in the response rate domain, while 3.8% had high ROB. Response rate information was missing for 46.2% of the measures.
Overall, HCV incidence and prevalence studies were of reasonable quality, but incidence studies were of lower precision. Nearly all studies had low ROB in at least one quality domain (99.0%), and 47.9% of all studies had low ROB in at least two of the three quality domains. Less than 3.6% of all studies had high ROB in two or three quality domains.

Discussion

We presented to our knowledge the first systematic review and synthesis of HCV incidence and prevalence across countries of the FC subregion of MENA. We also provided estimates for HCV prevalence at the national level and for various at risk populations. Our results suggest that HCV prevalence is at less than 1% among the general population across these countries (Table 4). Meanwhile, high prevalence levels were noted among hemodialysis, thalassemia and multi-transfused patients (Table 2). Genotypes 4 and 1 seem to be the most common genotypes circulating in these countries (Table 5 and S6 Fig).

Our estimates for the national HCV prevalence of less than 1% suggest that HCV levels in these countries are comparable to those in developed and other developing countries, but are towards the lower end of the global range [1, 2, 123]. These estimates also suggest that this sub-region appears to have the lowest HCV prevalence of all MENA subregions [7, 11–15]—substantially lower than in other MENA countries namely Egypt [6, 7] and Pakistan [8, 9].

A large fraction of HCV prevalence measures in the general population were among blood donors, and HCV prevalence in this normally healthy population may underestimate HCV prevalence in the population at large. In the USA, for example, HCV prevalence among blood donors [124] is substantially lower than that estimated in nationally-representative population-based surveys [125]. We conducted sensitivity analyses (not shown) to examine the impact of excluding blood donor data on our pooled estimates for HCV prevalence. For Iraq, HCV prevalence increased substantially from 0.2% to 0.8% with the exclusion of blood donors. Meanwhile, there were minor changes to the prevalence in Jordan (0.3% versus 0.2%) and Lebanon (0.2% versus 0.3%). Sensitivity analyses were not possible for Palestine and Syria due to the small number of studies among other general population groups (1 study in Palestine and 0 studies in Syria).

Overall, these results support our conclusion that HCV prevalence is likely to be below 1% among the population at large in each of the FC countries. It bears notice that our estimate for HCV prevalence in Iraq is substantially lower than that estimated recently using a different methodology in a global study (0.2% in our study versus 3.2% in Gower et al. study [22]). The difference in estimates arises from Gower et al. [22] basing their estimate on a single study [102] while our pooled prevalence was based on 99 studies, a large fraction of which were identified through our expanded search of data in non-indexed journals.

Despite the lower prevalence among the population at large, our findings indicate on-going transmission in at least some medical facilities. Exposures to hemodialysis [54, 84, 94] or blood transfusion [54, 122] were cited as risk factors for acquiring HCV. High HCV prevalence was generally observed among hemodialysis and thalassemia patients across countries (Table 2). High sero-conversion risks of up to 40% were found among hemodialysis patients in prospective studies (Table 1). Measurable HCV RNA prevalence among HCV antibody negative clinical populations were documented suggesting recent nosocomial HCV exposures (S3 Table). Higher HCV levels (compared to the general population) among health care workers, hospitalized populations, different clinical populations, diabetics, and dental providers were identified suggesting health care related HCV exposures (S2 Table). While some of the prevalent HCV exposures may date to times before the enforcement of more stringent blood screening and infection control protocols in these countries, the totality of the evidence supports the
conclusion of ongoing transmission in some clinical settings and through medical procedures. These results emphasize the importance of reinforcing blood screening and infection control in health care facilities.

Other HCV risk factors identified in this review included exposure to infected needles and sharp objects during tattooing and cupping procedures [122]. The latter, also known as *hijama*, is a common practice by community healers in MENA [18, 126]. There is also evidence elsewhere in MENA of a wider scope of community related HCV exposures as well as traditions of some professions, such as barbers, administering health care related procedures such as injections [7, 18, 127]. These findings highlight the relevance of controlling these exposures and insuring the safety of injections. This could be done, for example, by wide-scale replacement of current re-usable syringes with safety-engineered “smart” syringes [128, 129].

The ongoing political and military conflicts in this subregion (Iraq, Palestine, and Syria) introduce more challenges and serious barriers to the implementation of stringent blood screening and infection control in medical facilities and in communities. Shortages of medical supplies and trained human capital in these countries are often exacerbated by intermittent electricity and water supplies making the provision of even basic medical care difficult [42, 130–132]. Implications of these emergencies on current HCV transmission are unknown.

Injecting drug use appears to be the dominant driver of HCV incidence in many developed countries [133–135]. The estimated population proportion of injecting drug use among the adult population in FC ranges between 0.07% in Syria and 0.35% in Palestine [136]. The population proportion of injecting drug use in MENA as a whole is estimated at 0.24%; in the intermediate range compared to global levels [136]. Our search identified only few studies assessing the status of HCV infection among PWID and other drug users [18, 71, 89]. These showed HCV prevalence varying between 21% in Syria and 52.8% in Lebanon (Table 2). Relatively low HCV prevalence has been observed among prisoners, a fraction of whom are often drug users, in Iraq (0.6%) [137] and in Lebanon (3.4%) [113]. HCV prevalence among PWID in FC seems thus somewhat lower than that observed in other MENA countries and globally [23, 136]. With these overall limited data on HCV among PWID, it is difficult to judge the relative importance of injecting drug use as a driver of HCV incidence and prevalence in FC.

Migration dynamics within MENA may have played a role in HCV epidemiology in this subregion. This is specially so in relation to the epidemic in Egypt, the country with the largest HCV prevalence worldwide [6, 7]. The epidemic in Egypt is almost exclusively dominated by genotype 4 (>90%) [138], which is also a highly prevalent genotype in FC (Table 5). Genotype 4 in MENA appears to have a larger frequency in countries geographically close to Egypt and/or in countries that host or have hosted large migrant labor populations from Egypt [11, 12]. Iraq in particular, but also Jordan and Lebanon, have hosted or are currently hosting millions of Egyptian migrant labor [139–142]. A large fraction of the labor market in Iraq at some point consisted of Egyptian migrant workers who formed the backbone of the major infrastructure and developmental projects and agricultural sector in this country—such as during the era of the Iraq-Iran war [139–141]. Movement of Egyptian labor, who often came from rural areas most affected by HCV [7], may have contributed to higher circulation of genotype 4 in host countries, but has had a limited impact on HCV prevalence in these countries. FC countries appear to have some of the lowest HCV prevalence levels globally.

The Gaza strip, which borders Egypt, seems to be the part of FC most influenced by HCV dynamics in Egypt. The Gaza strip was under Egyptian rule prior to the 1967 Israeli occupation and shares strong historical, cultural, and economic ties with Egypt. With the protracted Israeli siege of Gaza, Egypt has become the main gateway for Gaza residents to the world and the country that provides essential services to the people of Gaza. Gazans often seek medical treatment in Egypt for conditions that cannot be treated in this largely impoverished district. It is
probably not surprising therefore that genotype 4 appears to be the dominant genotype in Gaza, and specially so among those with a history of travel, or of receiving medical care, including blood transfusions or surgical operations, in Egypt [118].

A substantial fraction of genotype 3 infections in FC were observed among PWID, affirming a global link between this genotype and injecting drug use [121, 138, 143]. Apart from Lebanon, very limited number of genotype 3 infections were identified (Table 5). One reason could be that PWID contribution to HCV incidence is not large in these countries, and/or that genotypes 4 and 1 are the dominant genotypes circulating among PWID. An alternative explanation, and possibly a more plausible one, is that existing studies of genotypes have not yet reached this largely hidden population whose contribution to HCV incidence and prevalence remains poorly understood.

Lebanon and Syria showed higher genotype diversity with genotype 5 only detected in these countries, and genotype 2 being more prevalent in Lebanon than in the rest of FC (Table 5). These findings are consistent with the large scale emigration rates and diaspora populations of these two countries globally—specifically so for Lebanon. Such population movements may provide avenues for genotypes that are prevalent in other parts of the world, say in West Africa and Latin America for genotype 2 [121, 141] and South Africa for genotype 5 [121, 138], to be introduced into circulation in some of these countries.

Our systematic review and meta-analyses are limited by the variability in quantity and quality of studies across countries. There were few studies that assessed HCV incidence and some countries did not have sufficient number of prevalence measures in some of the at risk populations to warrant conduct of meta-analyses. With the convenience sampling in most studies, and the country-specific variability in frequency, specific population and geographical location of available data, the estimates may not be representative of the true HCV population prevalence. Data was also limited for some of the specific populations that play an important role in HCV epidemiology, most notably PWID. HCV RNA measures were limited in quantity and were often based on relatively small samples.

The number of genotyped infections was not large in all countries and available genotype data may not have captured the diversity and true frequency of genotypes across the different at risk populations in each country. For example, there were some differences, though minor, between the genotype frequencies identified here compared to those of two recent studies of global genotype distribution [22, 121]. The main source of differences appears to be the inclusion of more studies on HCV genotypes in our review, largely as a consequence of including regional and national databases in our search of non-indexed published literature (S3 and S6 Figs).

Our meta-analyses highlighted heterogeneity in effect size among included studies. This is not unexpected considering the differences in prevalence measures in terms of the specific population studied, sampling methodology and participant recruitment, age-group representation in the sample, year of study, location and assay used [12]. However, due to the relatively small number of outcome measures for each country, we were unable to conduct a meaningful multi-variable meta-regression analysis to identify sources of heterogeneity in effect size.

**Conclusions**

HCV prevalence in the population at large in FC appears to be below 1%, and is tending towards the lower end of the global range. HCV prevalence among high risk populations, such as hemodialysis and thalassemia patients, is considerable and the evidence indicates ongoing HCV transmission in at least some medical facilities. Genotypes 4 and 1 appear to be the most prevalent, and genotype distributions suggest a role for recent migrations in the circulation of
different genotypes across national borders. With the limitations in available data, infection levels among PWID and the contribution of this population to HCV incidence and prevalence remain uncertain. The implications of the ongoing military conflicts and ensuing emergencies in FC on current HCV transmission are unknown.

Further research is needed for a better understanding of the epidemiology of this infection in this MENA subregion. Elucidation of the role of key populations in HCV transmission, such as PWID, is needed. Conduct of nationally-representative population-based surveys to estimate HCV prevalence, delineate spatial variability in prevalence, identify modes of exposure, and assess HCV knowledge and attitudes, as has been done recently in Egypt [6, 144–148], will enhance our knowledge of the epidemiology of this infection in this part of the world.

Our findings inform planning of health service provision, articulation of HCV policy guidelines, and implementation of effective HCV programming to reduce HCV transmission and decrease the burden of its associated diseases. Since HCV exposures in FC are linked to specific settings, HCV prevention efforts should be targeted and focus on infection control in clinical settings and harm reduction among PWID. Adoption of the new World Health Organization guidelines for the use of safety-engineered syringes [128, 129] can also minimize exposure to HCV and other blood-borne pathogens.

Supporting Information

S1 Fig. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.
(TIF)

S2 Fig. Data sources and search criteria for systematically reviewing hepatitis C virus (HCV) incidence and prevalence in countries of the Fertile Crescent.
(TIF)

S3 Fig. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) genotypes in the Fertile Crescent countries, adapted from the PRISMA 2009 guidelines.
(TIF)

S4 Fig. Definitions and risk classification of populations identified through the systematic review.
(TIF)

S5 Fig. Description of quality assessment criteria and studies’ risk of bias (ROB) appraisal.
(TIF)

S6 Fig. Distribution of hepatitis C virus (HCV) genotypes and subtypes among HCV RNA positive individuals across countries of the Fertile Crescent. Data on individuals infected with multiple HCV genotypes was only available for Iraq, Lebanon and Palestine.
(TIF)

S7 Fig. Forest plot presenting the results of the meta-analysis of hepatitis C virus (HCV) prevalence measures among the general population in Iraq.
(TIF)

S8 Fig. Forest plots presenting the results of the meta-analyses of hepatitis C virus (HCV) prevalence measures among the general population in: A) Jordan, B) Lebanon, and C) Syria.
(TIF)
S9 Fig. Forest plot presenting the results of the meta-analysis of hepatitis C virus (HCV) prevalence measures among the general population in Palestine.

(TIF)

S1 Table. Lists of variables extracted from relevant reports with hepatitis C virus (HCV) incidence and/or prevalence information or with HCV genotype information.

(DOCX)

S2 Table. Studies reporting hepatitis C virus (HCV) prevalence among populations at intermediate risk, special clinical populations, and mixed populations in countries of the Fertile Crescent.

(DOCX)

S3 Table. Studies reporting hepatitis C virus (HCV) RNA prevalence in countries of the Fertile Crescent.

(DOCX)

S4 Table. Summary of precision and risk of bias assessment for hepatitis C virus (HCV) incidence and prevalence measures extracted from eligible reports.

(DOCX)

S5 Table. Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) incidence measures in countries of the Fertile Crescent.

(DOCX)

S6 Table. Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) prevalence measures among populations at high risk in countries of the Fertile Crescent.

(DOCX)

S7 Table. Precision and risk of bias (ROB) assessment for individual hepatitis C virus (HCV) prevalence measures among the general population in countries of the Fertile Crescent.

(DOCX)

S8 Table. Precision and risk of bias (ROB) assessment of individual hepatitis C virus prevalence measures among populations at intermediate risk and among special clinical populations in countries of the Fertile Crescent.

(DOCX)

Acknowledgments

The authors would like to thank Dr. Jane Messina for providing us with information on HCV genotypes.

Author Contributions

Conceived and designed the experiments: LJA-R. Analyzed the data: HC KC. Wrote the paper: HC LJA-R.

References

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57 (4):1339–42. doi: 10.1002/hep.26141 PMID: 23172780.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011; 17 (2):107–15. doi: 10.1111/j.1469-0691.2010.03432.x PMID: 21091831.

3. World Health Organization. Hepatitis C: fact sheet Geneva, Switzerland [updated April 2014; cited 2015 02/02]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.

4. Centers for Disease Control and Prevention. Hepatitis C Atlanta, USA [updated August 1, 2013; cited 2015 02/02]. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c.

5. A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver Diseases November 1–5, 2013 • Washington DCSpecial Reporting on: Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in Difficult-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA Gastroenterology & Hepatology. 2014; 10(1 Suppl 1):1–19.

6. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo: Egyptian Ministry of Health, National Population Council, El-Zanaty and Associates, and ORC Macro; 2009. 431 p.

7. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infectious diseases. 2013; 13:288. doi: 10.1186/1471-2334-13-288 PMID: 23799878; PubMed Central PMCID: PMC3702438.

8. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiah li-sharq al-mutawassit. 2010; 16 Suppl:S15–23. PMID: 21495584.

9. Umar M, Bushra HT, Ahmad M, Data A, Ahmad M, Khurram M, et al. Hepatitis C in Pakistan: a review of available data. Hepatitis monthly. 2010; 10(3):205–14. PMID: 22308140; PubMed Central PMCID: PMC3269085.

10. Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-Raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. Systematic reviews. 2014; 3:146. Epub 2014/12/18. doi: 10.1186/2046-4053-3-146 PMID: 25516265; PubMed Central PMCID: PMC4274704.

11. Mohamoud YA, Riome S, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analyses (under preparation). 2015.

12. Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the maghreb region: systematic review and meta-analyses. PloS one. 2015; 10(3):e0121873. doi: 10.1371/journal.pone.0121873 PMID: 25803848; PubMed Central PMCID: PMC4372394.

13. Chaabna K., Kouyoumjian S., Abu-Raddad LJ. Hepatitis C virus prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. Systematic reviews. 2014; 3:146. Epub 2014/12/18. doi: 10.1186/2046-4053-3-146 PMID: 25516265; PubMed Central PMCID: PMC4274704.

14. Chemaitelly H, Mahmud S, Abu-Raddad LJ. The epidemiology of hepatitis C in Afghanistan: Systematic review and meta-analyses (under preparation). 2015.

15. Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses (under preparation). 2015.

16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009; 6(7):e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072; PubMed Central PMCID: PMC2705759.

17. Chaabna K, Mohamoud YA, Chemaitelly H, Mumtaz GR, Abu-Raddad LJ. Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. 2014. Available at: http://www.crd.york.ac.uk/NIHR_PROSPERO/display_record.asp?ID=CRD42014010318#.VrPkJHuEqUd 2014.

18. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, Tawil O. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: Time for strategic action. World Bank/UNAIDS/WHO Publication, editor. Washington DC: The World Bank Press; 2010.

19. Abu-Raddad LJ, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, et al. Epidemiology of HIV infection in the Middle East and North Africa. AIDS (London, England). 2010; 24 Suppl 2:S5–23. doi: 10.1097/01.aids.0000386729.56683.33 PMID: 20610949.
20. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359–62. PMID: 2523562.

21. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244(4902):362–4. PMID: 2496467.

22. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45–57. doi:10.1016/j.jhep.2014.07.027 PMID: 25086286.

23. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378(9791):571–83. doi:10.1016/S0140-6736(11)61097-0 PMID: 21802134; PubMed Central PMCID: PMC3285467.

24. The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions. Hoboken (New Jersey): Wiley-Blackwell; 2008.

25. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. Ann Math Statist. 1950; 21(4):607–11.

26. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC research notes. 2012; 5:52. Epub 2012/01/24. doi:10.1186/1756-0500-5-52 PMID: 22264277; PubMed Central PMCID: PMC3296675.

27. Borenstein M. Introduction to meta-analysis. Chichester, U.K.: John Wiley & Sons; 2009. xxviii, 421 p.

28. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003; 327:557–60.

29. Shannon CE. The mathematical theory of communication. 1963. MD computing: computers in medical practice. 1997; 14(4):306–17. PMID: 9230594.

30. IBM Corporation. IBM SPSS Statistics for Windows, Version 22.0. Armonk, New York: IBM Corporation; 2013.

31. R Core Team. R 3.1.2: A language and environment for statistical computing. Vienna, Austria2014.

32. Additional country-level data provided through the MENA HIV/AIDS Epidemiology Synthesis Project database by the World Health Organization Regional Office for the Eastern Mediterranean. 2014.

33. Palestinian Health Information Center. Health Annual Report 2013. URL:http://www.moh.ps/?lang=1&page=4&id=939: 2014.

34. Palestinian Health Information Center. Health Annual Report 2009. URL: http://www.moh.ps/?lang=1&page=4&id=150: 2010.

35. Palestinian Health Information Center. Health Annual Report 2007. URL: http://www.moh.ps/?lang=1&page=4&id=139: 2008.

36. Palestinian Health Information Center. Health Annual Report 2006. URL: http://www.moh.ps/?lang=1&page=4&id=142: 2007.

37. Palestinian Health Information Center. Health Annual Report 2005. URL: http://www.moh.ps/?lang=1&page=4&id=9: 2006.

38. Palestinian Health Information Center. Health Annual Report 2003. URL: http://www.moh.ps/?lang=1&page=4&id=137: 2004.

39. Batieha A, Abdallah S, Maghaireh M, Awad Z, Al-Akash N, Batieheh A, et al. Epidemiology and cost of haemodialysis in Jordan. Eastern Mediterranean Health Journal. 2007; 13(3):654–63. PMID: 2007356348.

40. Al-Rubaie H. MH., Malik A.S. Seroconversion rate of hepatitis C virus infection among haemodialysis patients in Al-Kadhimiya Teaching Hospital (dialysis unit). Iraqi Journal of Medical Sciences. 2011; 9 (4):343–9.

41. Al-Ali N. AA., AL-Kayatt T. N. Seroprevalence of hepatitis B & C in pediatric malignancies. Iraqi Post-graduate Medical Journal. 2014; 13(2):262–7.

42. Al-Jadiry M. Viral hepatitis markers screen in children with acute lymphoblastic leukemia experience of Children Welfare Teaching Hospital. Journal of the Faculty of Medicine of Baghdad. 2008; 50 (2):223–30.

43. Al-Ani M. H., Rasul T. H. Hepatitis B and C viral infections in children with acute leukemia in Erbil city. Journal of the Arab Board of Health Specializations. 2011; 12(1):21–9.
44. Al-Kubaisy W. A., Niazi A., Kubba K. Lack of mother-to-newborn transmission of hepatitis C virus in Iraqi women: a prospective study with hepatitis C virus RNA testing. Journal of the Arab Board of Health Specializations. 2000; 2(2).

45. Al-Kubaisy WA, Al-Naib KT, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassemia. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2006; 12(1–2):204–10. Epub 2006/10/14. PMID: 17037239.

46. Abdul-Aziz M, Abdul-Karem K, Shamse-El-Den S, Al-Moula GA. Prevalence of hepatitis B & C among people attending Kirkuk Public Health Laboratory. Al-Taqani. 2001; 23(3):6–15.

47. Abdullah B. A., Khaled M. D., Maarouf M. N. Detection of hepatitis C virus (HCV) by ELISA, RIBA and Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) technique among kidney dialysis patients in Nineveh governorate/Iraq. Science Journal of Thi-Qar 2012; 3(2):55–67.

48. Abdullah AM, Hardan A, Latif II. Genotyping of hepatitis C virus isolates from Iraqi hemodialysis patients by reverse transcription-PCR and one step nested RT-PCR. Diyala Journal of Medicine. 2012; 3(1):9–18.

49. Al-Dulaimi S. B. K., Al-Ubadi A. E., Al-Ubadi A. E., Al-Bayatti E. N., Al-Saday S. D. K. Toxoplasma gondii, HCV, and HBV seroprevalence in Haemodialysis patients with chronic renal failure in Al-Kindy Hospital Baghdad, Iraqi. Al-Mustansiriyyah Journal of Science. 2012; 23(5):33–8.

50. Al-Mashhadani JI. Hepatitis C virus infection among haemodialysis patients in Al-Anbar governorate. Iraqi Journal of Community Medicine. 2007; 20(1):20–3.

51. Khattab OS. Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in an Iraqi renal transplant center. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2008; 19(1):110–5. Epub 2007/12/19. PMID: 18087139.

52. Khattab O. S. How to decrease the prevalence of hepatitis C in Iraqi hemodialysis patients. The Iraqi Postgraduate Medical Journal. 2010; 9(1):31–5.

53. Mnuti J. K., Al-Abbudi F. A. Hepatitis C virus infection assessment among chronic hemodialysis patients in Al-Kadhamiya Teaching Hospital. Iraqi Postgraduate Medical Journal. 2011; 10(4):460–4.

54. Ramzi Z. S., Abdulla A. A., Al-Hadithi T., Al-Tawil N. Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in Sulaimani. Zanco Journal of Medical Sciences. 2010; 14(1):44–50.

55. Shihab SS, Al-Hmudi HA, Al-Edani HS, Mahdi KH. Viral hepatitis infections in Basrah haemodialysis unit: serological diagnosis and viral loading. European Journal of Experimental Biology. 2014; 4(2):106–12.

56. Al-Beldawi D. H. The risk factors of inhibitor development and hepatitis C virus among hemophilic patients in Children Welfare Teaching Hospital. Journal of the Faculty of Medicine of Baghdad. 2010; 52(1):4–8.

57. Al-Thwani A. N., Al-Yassiri A. S. Using ELISA & ELFA for diagnosis of infection with hepatitis C, B and HIV viruses among Iraqi haemophilic patients. Iraqi Journal of Biotechnology. 2006; 5(1):70–84.

58. Muhsin M. A., Abdul-Husin I. F. Seroprevalence of hepatitis B and C among thalassemic, haemophilic patients in Babylon Govenorate-Iraq. Medical Journal of Babylon. 2013; 10(2):445–54.

59. Tarky A. M., Akram W., Al-Naaimi A. S., Omer A. R. Epidemiology of viral heaptitis B and C in Iraq: a national survey 2005–2006. Zanco Journal of Medical Sciences. 2013; 17(1):370–80.

60. Al-Mashhadani J. I., Al-Hadithi T. S., Al-Diwan J. K., Omer A. R. Sociodemographic characteristics and risk factors of hepatitis B and C among Iraqi health care workers. Journal of the Faculty of Medicine of Baghdad. 2009; 51(3):308–11.

61. Al-Saad T, Al-Alousi BM, Khalaf NM, Abdul Razak W. Prevalence of hepatitis B and C viruses among medical staff in Ramadi General Hospital. Al-Anbar Medical Journal. 2009; 7(1):69–75.

62. Hassan ZM, Wahsheh MA, Shishani KR, Pryor ER. Hepatitis needs assessment among Jordanian healthcare workers. International nursing review. 2008; 55(2):142–7. Epub 2008/05/15. doi: 10.1111/j.1466-7657.2007.00583.x PMID: 18477097.

63. Noaman N.G. Prevalence of hepatitis C virus infection among blood donors and certain risky groups in Diyala Province. Diyala Journal of Medicine. 2012; 2(1):46–92.

64. Saadoon A. A. Prevalence of viral hepatitis B and C among selected group in Thi-Qar. Thi-Qar Medical Journal. 2012; 6(1):79–89.

65. Hussain AI, Anizy HH. Prevalence of viral hepatitis B and C among dentistry professionals in Anbar province. Journal of Al-Anbar University for Pure Science. 2008; 2(2):18–24.
66. Al-Marzooqi A. H., Shemrmran A. R., Al-Tae Z. M., Al-Nafee M. K. Bacterial and viral infections associated with thalassemia in Hillah city. Journal of Al-Qadisiyah for Pure Science. 2009; 14(3):1–15.

67. Albaitushi A., Tariq G., Mahmood M. Viral infections and diabetes mellitus. Journal of the Biotechnology Research Center. 2011; 5(3):29–33.

68. Al-Sweedan SA, Jaradat S, Amer K, Hayaineh W, Haddad H. Seroprevalence and genotyping of hepatitis C virus in multiple transfused Jordanian patients with beta-thalassemia major. [Turkish]. Multipel transfuzyon uygulanlan beta-talasemi majorluurdunun hastalarda hepatitis C virusunun seroprevalansini (dotless) ve genotiplemesi. Turkish Journal of Hematology. 2011; 28(1):47–51. doi: http://dx.doi.org/10.5152/ht.2011.05 PMID: 21173285.

69. Quadan A. Prevalence of anti hepatitis C virus among the hospital populations in Jordan. The new microbiologia. 2002; 25(3):269–73. Epub 2002/08/14. PMID: 12173766.

70. Al-Sheyyab M, Batieha A, El-Khateeb M. The prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers in multi-transfused patients. Journal of tropical pediatrics. 2001; 47(4):239–42. Epub 2001/08/29. PMID: 11523766.

71. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virology journal. 2010; 7:96. Epub 2010/05/15. doi: 10.1186/1471-2172-7-96 PMID: 20465786; PubMed Central PMCID: PMC2885342.

72. Abdelnoor GE, Matar GM, Sharara HM, Abdelnoor AM. Detection of anti-hepatitis C-virus antibodies and hepatitis C-virus RNA in Lebanese hemodialysis patients. European journal of epidemiology. 1997; 13(8):863–7. Epub 1998/02/26. PMID: 9476813.

73. Naman RE, Mansour I, Klayme S, Khalil G. [Hepatitis C virus in hemodialysis patients and blood donors in Lebanon]. Le Journal medical libanais The Lebanese medical journal. 1996; 44(1):4–9. Epub 1996/01/01. PMID: 8963318.

74. Inati A, Musallam K, Taha M, Ziade F, Taher A. Magnetic resonance imaging T2* in the evaluation of cardiac Iron overload in patients with sickle cell disease. Haematologica. 2009; 94:511–2. PMID: 70013481.

75. Ramia S, Koussa S, Taher A, Haraki S, Klayme S, Sarkis D, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. Annals of tropical medicine and parasitology. 2002; 96(2):197–202. Epub 2002/06/26. doi: 10.1179/000349802125000439 PMID: 12080981.

76. Ramia S, Klayme S, Naman R. Infection with hepatitis B and C viruses and human retroviruses (HTLV-I and HIV) among high-risk Lebanese patients. Annals of tropical medicine and parasitology. 2003; 97(2):187–92. Epub 2003/06/14. doi: 10.1179/000349803235001363 PMID: 12083874.

77. Araj GF, Khoury-Baz EE, Barada KA, Nassif RE, Alami SY. Hepatitis C virus: prevalence in Lebanese women. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 1995; 17(6):548. Epub 1997/01/01. doi: 10.1080/014436197685560 PMID: 8676356.

78. Irani-Hakime N, Musharrafieh U, Samaha H, Almawi WY. Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997–2003. American journal of infection control. 2006; 34(4):241–3. Epub 2006/05/09. doi: 10.1016/j.ajic.2005.06.009 PMID: 16679184.

79. Irani-Hakime N, Tamim H, Samaha H, Almawi WY. Prevalence of antibodies against hepatitis C virus among blood donors in Lebanon, 1997–2000. Clinical and laboratory haematology. 2001; 23(5):317–23. Epub 2001/11/13. PMID: 11703415.

80. Nabulsli MM, Araj GF, Farah AE, Khalil AM. Hepatitis C virus antibodies in pregnant Lebanese women. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 1997; 17(6):548. Epub 1997/01/01. doi: 10.1080/014436197685560 PMID: 15511954.

81. Ramia S, Ramlawi F, Kanaan M, Klayme S, Naman R. Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors. Epidemiology and infection. 2005; 133(4):695–9. Epub 2005/07/30. PMID: 16050516; PubMed Central PMCID: PMC2870298.

82. Salem Z, Nuwayri-Salti N, Ramlawi F, Ramia S. Hepatitis C virus infection in Lebanese patients with B-cell non-Hodgkin's lymphoma. European journal of epidemiology. 2003; 18(3):251–3. Epub 2003/06/13. doi: 10.1023/a:1023380316098 PMID: 12800950.

83. Tamim H, Irani-Hakime N, Aoun JP, Khoury S, Samaha H, Almawi WY. Seroprevalence of hepatitis C virus (HCV) infection among blood donors: a hospital-based study. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis. 2001; 24(1):29–35. Epub 2001/08/23. PMID: 11515608.

84. Baddoura R, Haddad C, Germanos M. Hepatitis B and C seroprevalence in the Lebanese population. Eastern Mediterranean health journal = La revue de sante de la Mediteranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2002; 8(1):150–6. Epub 2004/08/28. PMID: 15330570.
85. Yaghi C, Sharara AI, Rassam P, Moucari R, Honein K, BouJaoude J, et al. Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. World Journal of Gastroenterology. 2006; 12(22):3575–80. PMID: 17063193.

86. Otrock ZK, Saab J, Atifmos G, Nasr F, Farhat FS, Khairallah S, et al. A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. Pathology and Oncology Research: POR. 2013; 19(4):715–22. Epub 2013/05/09. doi: 10.1007/s12253-013-9634-0 PMID: 23653112.

87. Dumaidi K, Al-Jawabreh A. Prevalence of occult HBV among hemodialysis patients in two districts in the northern part of the West Bank, Palestine. Journal of medical virology. 2014; 86(10):1694–9. doi: 10.1002/jmv.24008 PMID: 24992542.

88. El-kader YE-OA, Elmanarna AA, Ayesh BM. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. Virology Journal. 2010; 7:210. Epub 2010/09/03. doi: 10.1186/1743-422x-7-210 PMID: 20809985; PubMed Central PMCID: PMC2942824.

89. Stuhlhofer A, Chetty A, Rabie RA, Jwehan I, Ramlawi A. The prevalence of HIV, HBV, HCV, and HIV-related risk-taking behaviors among Palestinian injecting drug users in the East Jerusalem Governorate. Journal of urban health: bulletin of the New York Academy of Medicine. 2012; 89(4):671–6. Epub 2012/06/08. doi: 10.1007/s11524-012-9672-z PMID: 22674463; PubMed Central PMCID: PMC3595135.

90. Shemer-Avni Y, el Astal Z, Kemper O, el Najjar KJ, Yaari A, Hanuka N, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. Journal of medical virology. 1998; 56(3):230–3. Epub 1998/10/23. PMID: 9783498.

91. Novack L, Shinar E, Safi J, Soliman H, Yaari A, Galai N, et al. Evaluation of pooled screening for anti-HCV in two blood service settings. Tropical Medicine and International Health. 2007; 12(3):415–21. Epub 2007/02/23. doi: 10.1111/j.1365-3156.2006.01810.x PMID: 17313513.

92. Abdulkarim AS, Zein NN, Germer JJ, Kolbert CP, Kabbani L, Krajnik KL, et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. The American journal of tropical medicine and hygiene. 1998; 59(4):571–5. Epub 1998/10/28. PMID: 9794032.

93. Moukeh G, Yacoub R, Fahdi F, Rastam S, Albitar S. Epidemiology of hemodialysis patients in Aleppo city, Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2009; 20(1):140–6. Epub 2008/12/30. PMID: 19112237.

94. Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection. 2001; 29(5):262–5. Epub 2001/11/02. PMID: 11688903.

95. Syria Mental Health Directorate and National AIDS Programme (of Syrian Ministry of Health). Assessment of HIV risk and sero-prevalence among drug users in greater Damascus. Syrian Ministry of Health, United Nations Office on Drugs and Crime, and the Joint United Nations Programme on HIV/AIDS, 2008.

96. Ali T, Schwed JF. Registry of hemophilia and other bleeding disorders in Syria. Haemophilia. 2012; 18(6):851–4. Epub 2012/06/08. doi: 10.1111/j.1365-2516.2012.02862.x PMID: 22672010.

97. Othman BM, Monem FS. Prevalence of hepatitis C virus antibodies among intravenous drug abusers and prostitutes in Damascus, Syria. Saudi medical journal. 2002; 23(4):393–5. Epub 2002/04/16. PMID: 11953762.

98. National AIDS Programme and Central Statistics Bureau (of Syrian Ministry of Health). Knowledge, attitude, and professional behavior of health care workers around certain blood-borne diseases including AIDS and hepatitis B and C. Syrian Ministry of Health, United Nations Development Programme, and the World Health Organization, date unknown.

99. al-Azmeh J, Frosner G, Darwish Z, Bashour H, Monem F. Hepatitis E in Damascus, Syria. Infection. 2001; 29(5):262–5. Epub 2001/11/02. PMID: 11688903.

100. Obied H.M., Alrodhan M.A., Mallah M.O. Molecular and immunological detection of hepatitis C virus infection among blood donors in Al-Muthanna province-Iraq. International Journal of Advanced Research. 2014; 2(6):295–315.

101. Tawfeeq WF. Detection of hepatitis C virus infection and genotypes among seropositive blood donors by polymerase chain reaction in babylon Governorate, Iraq. Medical Journal of Babylon. 2013; 10(1):25–37.

102. Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2002; 8(2–3):239–44. Epub 2004/09/02. PMID: 15339110.

103. Rashdan A, Hijjawi S, Jadallah K, Matalka I. Prevalence of hepatitis C virus antibodies among blood donors in Northern Jordan. Jordan Medical Journal. 2008; 42(3):179–83. PMID: 1809005380.
104. Al-Kubaisy W. A., Obaid K. J., Noor N. M., Ibrahim N. S., Al-Azawi A. A. Hepatitis C virus prevalence and genotyping among hepatocellular carcinoma patients in Baghdad. Asian Pacific journal of Cancer Prevention. 2014; 15(18):7725–30. PMID: 25292053

105. Chironna M, Germinario C, Lopalco PL, Carrozzi F, Barbuto S, Quarto M. Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey. Infection. 2003; 31(2):70–4. Epub 2003/04/12. doi: 10.1007/s15010-002-3100-3 PMID: 12682810.

106. Al-Kubaisy WA, Al-Naib KT, Habib MA. Prevalence of HCV/HIV co-infection among haemophilia patients in Baghdad. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2006; 12(3–4):284–9. Epub 2006/10/14. PMID: 17037693.

107. Othman AA, Elsaa AA, Markous RD, Ahmed BD, Al-Allawi NA. Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian journal of transfusion science. 2014; 8(1):32–4. Epub 2014/03/29. doi: 10.4103/0973-6247.126687 PMID: 24678171; PubMed Central PMCID: PMC3943142.

108. Abbas Y. A., Aubaid A. H., Hamad B. J. Determination of hepatitis C viral load and genotypes by Real-Time and RT-PCR at Thi-Qar province. Al-Qadisiah Medical Journal. 2013; 9(15):250–64.

109. Al-hemiary R. M. The diagnostic value of hepatitis C genotyping by Real time-PCR in Iraqi patients. Iraq Journal of Market Research and Consumer Protection. 2012; 4(2):159–67.

110. Khalid M.D., Abdullah B. A. Hepatitis C virus genotypes in Iraq. Iraqi Journal of Biotechnology. 2012; 11(2):475–80.

111. Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. Journal of medical microbiology. 2002; 51(8):700–4. Epub 2002/08/13. PMID: 12171303.

112. Hamoudi W, Ali SA, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. Journal of epidemiology and global health. 2013; 3(2):67–71. Epub 2013/07/17. doi: 10.1016/j.jegh.2013.02.003 PMID: 23856567.

113. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. Journal of infection in developing countries. 2010; 4(3):144–9. Epub 2010/03/31. PMID: 20351454.

114. Matar GM, Sharara HM, Abdelnour GE, Abdelnoor AM. Genotyping of hepatitis C virus isolates from chronically infected Lebanese patients: a hospital-based study. Journal of epidemiology and infection. 2007; 135(3):427–32. Epub 2006/07/20. doi: 10.1017/s0950268806006911 PMID: 16848924; PubMed Central PMCID: PMC2870582.

115. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. British journal of haematology. 2005; 130(4):644–6. Epub 2005/08/16. doi: 10.1111/j.1365-2457.2005.05645.x PMID: 16098081.

116. Sharara AI, Ramia S, Ramlawi F, Fares JE, Klayme S, Naman R. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. Epidemiology and infection. 2007; 135(3):427–32. Epub 2006/07/20. doi: 10.1017/s0950268806006911 PMID: 16848924; PubMed Central PMCID: PMC2870582.

117. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. British journal of haematology. 2005; 130(4):644–6. Epub 2005/08/16. doi: 10.1111/j.1365-2457.2005.05645.x PMID: 16098081.

118. Ayesh BM, Zourob SS, Abu-Jadallah SY, Shemer-Avni Y. Most common genotypes and risk factors for HCV in Gaza strip: a cross sectional study. Virology journal. 2009; 6:105. Epub 2009/07/18. doi: 10.1186/1743-422x-6-105 PMID: 19607718; PubMed Central PMCID: PMC2716328.

119. Antaki N, Haddad M, Kebbewar K, Abdelwahab J, Hamed O, Aaraj R, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiology and infection. 2009; 137(1):79–84. Epub 2008/03/19. doi: 10.1017/s095026880800054x PMID: 18348288.

120. Karadat A. Hepatitis C genotypes in Syrian refugee patient in Turkey. Hepatology International. 2015; 9(1 SUPPL. 1):S276. http://dx.doi.org/10.1002/hep.27259 PMID: 25069959; PubMed Central PMCID:PMC403918.

121. Khaleel H. A., Turky A. M., Al-Naaimi A. S., Jail R. W., Mekhief O. A., Abdul Kareem S., et al. Prevalence of HBsAg and anti HCV Ab among patients with suspected acute viral hepatitis in Baghdad, Iraq in 2010. Epidemiology Reports. 2014; 1(1). doi: 10.7243/2054-9911-1-1
123. Comberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver international: official journal of the International Association for the Study of the Liver. 2011; 31 Suppl 2:30–60. Epub 2011/06/18. doi: 10.1111/j.1478-3231.2011.02539.x PMID: 21651702.

124. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010; 50(7):1495–504. doi: 10.1111/j.1537-2995.2010.02622.x PMID: 20345570.

125. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Annals of internal medicine. 2014; 160(5):293–300. doi: 10.7326/M13-1133 PMID: 24737271.

126. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989–2013); Do they differ in Egypt? Liver international: official journal of the International Association for the Study of the Liver. 2015; 35(2):489–501. doi: 10.1111/liv.12617 PMID: 24923487.

127. Mohamoud YA, Miller FD, Abu-Raddad LJ. Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker. World journal of gastroenterology: WJG. 2014; 20(36):12734–52. doi: 10.3748/wjg.v20.i36.12734 PMID: 25278675; PubMed Central PMCID: PMC4177460.

128. World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings. 2015 WHO/HIS/SDS/2015.5.

129. WHO calls for worldwide use of “smart” syringes [Internet]. 2015; February 23. Available from: http://www.who.int/hac/crises/news/releases/2015/injection-safety/en/

130. World Health Organization. Conflict and humanitarian crisis in Iraq Geneva, Switzerland: World Health Organization; 2014 [cited HQ/PEC/ERM/SCT/2014.4/PHRA 23/02/2015]. Available from: http://who.int/hac/crises/irq/iraq_phra_24october2014.pdf.

131. World Health Organization. Annual report of the Regional Director 2013: Emergency preparedness and response Switzerland, Geneva2013 [23/02/2015]. Available from: http://www.emro.who.int/annual-report/2013/emergency-preparedness-and-response.html.

132. World Health Organization. Health emergency highlights. Emergency Risk Management and Humanitarian Response. 2014;(19. ).

133. Alter MJ. Epidemiology of hepatitis C virus infection. World journal of gastroenterology: WJG. 2007; 13(17):2436–41. PMID: 17552026; PubMed Central PMCID: PMC4146761.

134. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious diseases. 2005; 5(9):558–67. doi: 10.1016/S1473-3099(05)70216-4 PMID: 16122679.

135. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of internal medicine. 2006; 144(10):705–14. PMID: 16702586.

136. Mumtaz GR, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver international: official journal of the International Association for the Study of the Liver. 2011; 31 Suppl 2:30–60. Epub 2011/06/18. doi: 10.1111/j.1478-3231.2011.02539.x PMID: 21651702.

137. Hassan A. S. Prevalence of anti-hepatitis C virus antibodies among blood donors and risky groups in Diyalal. Journal of the Faculty of Medicine of Baghdad. 2008; 50(4):467–70. PMID:16702586.

138. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2006; 10(4):272–7. doi: 10.1016/j.ijid.2005.07.008 PMID: 16564719.

139. Taylor E. Egyptian Migration and Peasant Wives Middle East Research and Information Project 124. Washington: Middle East Research and Information Project.

140. Feiler G. Migration and Recession—Arab Labor Mobility in the Middle-East, 1982–89. Popul Dev Rev. 1991; 17(1):134–55. doi: 10.1016/j.pop.1991.02.00007. PMID: WOS:A1991FP82100007.

141. Humphrey M. Migrants, workers and refugees: the political economy of population movements in the Middle East. Middle East report. 1993;(181: ):2–7. PMID: 12179391.

142. International Organization for Migration. Migration and development in Egypt. 2010.

143. Pawlowsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. The Journal of infectious diseases. 1995; 171(6):1607–10. PMID: 7769300.
144. Cuadros DF, Branscum AJ, Miller FD, Abu-Raddad LJ. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology. 2014; 60(4):1150–9. doi:10.1002/hep.27248 PMID: 24913187; PubMed Central PMCID: PMC4282472.

145. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(33):14757–62. doi:10.1073/pnas.100877107 PMID: 20696911; PubMed Central PMCID: PMC2930444.

146. Chemaitelly H, Abu-Raddad LJ, Miller FD. An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. PloS one. 2013; 8(7):e69803. doi:10.1371/journal.pone.0069803 PMID: 23922806; PubMed Central PMCID: PMC3726777.

147. Benova L, Awad SF, Miller FD, Abu-Raddad LJ. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology. 2015; 61(3):834–42. doi:10.1002/hep.27596 PMID: 25366418; PubMed Central PMCID: PMC4365684.

148. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. Journal of viral hepatitis. 2012; 19(8):560–7. doi:10.1111/j.1365-2893.2011.01576.x PMID: 22762140.

149. Abdul-Karim E. T. The prevalence of hepatitis in patients with congenital coagulation disorders. Journal of the Arab Board of Health Specializations. 2011; 12(3):9–14.

150. Abed B. A. Prevalence of hepatitis C virus (HCV) among thalassemia patients in Ibn Al-Balady Hospital. Journal of Al-Nahrain University. 2010; 13(1):121–6.

151. Albahadle AK. J., Abdul-Abass A., Ali A. H. Prevalence of hepatitis C infection among multitransfused thalassemia major patients in Ibn-AlBalady center for thalassemia. Al-Qadisiah Medical Journal. 2013; 9(15):73–84.

152. Al-Barzinji R M. Patients with childhood leukemia are at high risk for transfusion-transmitted HBV and HCV infections. The Iraqi Postgraduate Medical Journal. 2006; 5(4):442–6.

153. Al-Greti S. H. H. Prevalence of hepatitis C viral infection among beta-thalassemia patients at Karbala governorate. Journal of Babylon University for Pure and Applied Sciences. 2013; 21(8):2801–5.

154. Al-Juboori L.F. Hepatitis C virus in thalassemia patients in Tikrit. Medical Journal of Tikrit. 2012; 1(181):95–100.

155. Al-Wtaify AS, Hassan MK. Prevalence of hepatitis C virus infection among multitransfused thalassemic children in Basrah—Iraq. Qatar Medical Journal. 2000; 9(2):58–61. PMID:2001134222.

156. Al-Zamili A. H., Al-Shebani A. M., Mohsin R. K. Prevalence of hepatitis C viral infection among multi-transfused thalassemic patients. Al-Qadisiah Medical Journal. 2009; 5(7):89–99.

157. Easa Z. O. Complications of high serum ferritin level after splenectomy in B thalassemic patients. Kufa Medical Journal. 2009; 12(1):243–50.

158. Fadhil R. S., Al-Khalidi S. J., Hussien S. M., Hasoon H. A., Hussien R. A., Alwan L. H. Complications of HBV, HCV and HIV infections in patients with Coolzye Anemia in Baghdad. Iraqi Journal of Cancer and Medical Genetics. 2012; 5(1):59–63.

159. Hashem N. A., Abdel-Rida Z. A., Taan G. M., Abdel-Hussein A. Spread of viral hepatitis among thalassemic patients in Maysan province. Al-Mustansiriyah Journal of Science. 2013; 24(3):51–6.

160. Khaled M. D. Prevalence of hepatitis B, hepatitis C and human immunodeficiency virus infection among Thalassemia patients in Ninawa Governorate/Iraq. Journal of Biotechnology Research Center. 2014; 8(2):11–3.

161. Khalid MD, Abdullah BA. Prevalence of anti-HCV antibodies among thalassemia patients in Mosul City, Iraq. Journal of Life Sciences. 2012; 6(5):489–91.

162. Mustafa B. The prevalence of hepatitis- B and C serological markers among patients with thalassemia in Mosul. Iraqi Journal of Pharmacy. 2010; 9 & 10(1):66–9.

163. Omer AR, Salih JI, Al-Nakshabandi AA. Frequency of blood-borne viral infections among leukemic patients in central Iraq. Saudi medical journal. 2011; 32(1):55–61. Epub 2011/01/08. PMID: 21212918.

164. Omer W. A., Jamealdin Z. A. Evaluation of some health and social parameters in Beta-thalassemia major patients in Ninawa governorate. Iraqi Medical Journal. 2011; 57(2):106–10.

165. Raham TF, Abdul Wahed SS, Alhaddad H. N. Prevalence of hepatitis C among patients with B-thalassemia in Diyala-Iraq. Al-Taqani. 2011; 24(4):113–20.

166. Al-Jamal M, Al-Qudah A, Al-Shishi KF, Al-Sarayreh A, Al-Quraan L. Hepatitis C Virus (HCV) infection in hemodialysis patients in the south of Jordan. Saudi journal of kidney diseases and transplantation.
an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2009; 20(3):488–92. Epub 2009/05/06. PMID: 19414962.

167. Batchoun RG, Al-Najdawi MA, Al-Taamary S. Anti-ENA antibody profile in hepatitis C patients undergoing hemodialysis. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2011; 22(4):682–8. Epub 2011/07/12. PMID: 21743211.

168. Ghunaimat M., Al-Mrayat Z., Abbadi R., Akash N. Point prevalence of hepatitis C antibodies among hemodialysis patients at king Hussein Medical Center. Journal of the Royal Medical Services. 2007; 14(2):63–7.

169. Said RA, Hamzeh YY, Meyhar NS, Rababah MS. Hepatitis C virus infection in hemodialysis patients in jordan. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 1995; 6(2):140–3. Epub 1995/04/01. PMID: 16583853.

170. Othman BM, Monem FS. Prevalence of hepatitis C virus antibodies among health care workers in Damascus, Syria. Saudi medical journal. 2001; 22(7):603–5. Epub 2001/08/02. PMID: 11479642.

171. Al-Juboury A. W. F., Salih H. A. L. M., Al-Assadi M. K., Ali A. M. Seroprevalence of Hepatitis B and C among blood donors in Mosul city. Al-Taqani. 2012; 25(2):70–72.

172. Al-Doori A.M. Prevalence of hepatitis B and hepatitis C among blood donors in Al-Anbar governorate. Journal of the Arab Board of Health Specializations. 2011; 12(1):35–38.

173. Al-Hamdani A.H., Al-Rawy S. K., Khamees H. A. Retrospective seroprevalence study of hepatitis B and C in Iraqi population at Baghdad: a hospital based study. Iraqi Journal of Community Medicine. 2012; (3):186–90.

174. Ali MK. Prevalence of hepatitis B and hepatitis C among blood donors in Baghdad, August 2007-December 2008. Journal of the Faculty of Medicine of Baghdad University. 2009; 51(4):419–22.

175. Al-Jebori A. S., Hassan A. S., Al-Duliami A. A. Seroprevalence of hepatitis B and hepatitis C virus infections in Diyala province during 2003–2008. Diyala Journal For Pure Science. 2010; 6(1):292–302.

176. Al-Hamdan A. H., Al-Rawy S. K., Khamees H. A. Retrospective seroprevalence study of hepatitis B and C in Iraqi blood donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006–2009. Saudi medical journal. 2011; 32(10):1046–50. Epub 2011/10/20. PMID: 22008925.

177. Al-Juboury A. W. F., Salih H. A. L. M., Al-Assadi M. K., Ali A. M. Seroprevalence of Hepatitis B and C among blood donors in Babylon Governorate-Iraq. Medical Journal of Babylon. 2010; 7(1):34–40.

178. Al-Kamil E. A., Al-Yassin A. K. Transfusion transmitted diseases among blood donors of Basrah blood bank. Journal of the Arab Board of Health Specializations. 2011; 12(1):35–40.

179. Ali MK. Prevalence of hepatitis B and hepatitis C among blood donors in Baghdad, August 2007-December 2008. Journal of the Faculty of Medicine of Baghdad University. 2009; 51(4):419–22.

180. Amin RM. Prevalence of HBV and HCV in blood donors in Mosul city. Al-Taqani. 2012; 25(2):70–7.

181. Ataallah TM, Hanan KA, Maysoun KS, Sadoon AA. Prevalence of hepatitis B and C among blood donors at Al-Fallujah blood bank. Diyala Journal For Pure Science. 2010; 6(1):292–302.

182. Hussein A. H. Seroprevalence of hepatitis B and C among blood donors in Sulaimani Major Blood Bank for the years 2006 and 2007: a comparative study. Journal of Zankoy Sulaimani. 2010; 13(1):15–20.

183. Fawzi N., Muhsin K. A. A. Screening for hepatitis B and hepatitis C viral infection among a sample of pregnant women in Al-Fallujah. Iraqi Medical Journal. 2011; 57(2):119–25.

184. Hamim S. S. A survey study for the prevalence of hepatitis B, A and C in Thi-Qar province for 2006–2010. Journal of College of Education for Pure Science. 2012; 2(1):262–77.

185. Hamim S. S. Seroprevalence of hepatitis B and C among blood voluntary in Iraq for 2008 and 2009. Journal of College of Education for Pure Science. 2012; 2(2):125–4.

186. Hussain A. K., Mohammed S. H., Abd K. H. Screening of hepatitis B and C viral markers in Iraqi patients with proteinuria. Iraqi Postgraduate Medical Journal. 2008; 7(4):362–8.

187. Hussein A. H. Seroprevalence of hepatitis B and C viruses among blood donors in Sulaimani Major Blood Bank for the years 2006 and 2007: a comparative study. Journal of Zankoy Sulaimani. 2010; 13(1):15–20.

188. Hussein S. M., Hasan A. Does hepatitis C virus infection is a relevant factor for thyroid dysfunction. Diyala Journal for Pure Science. 2010; 6(3):140–5.

189. Jassim A. N., Abdul-Hadi A. M., Al-Waysi S. A. Epidemiological study of viral hepatitis / Chibayish Marsh Reality in Iraq. Journal of Baghdad for Science. 2011; 8(1):23–8.
190. Naji MY, Abdulzahra AA, Hmood AR. Prevalence of viral hepatitis B and C in newly married persons. Kufa Journal for Nursing Sciences. 2013; 3(3).

191. Richter C, Ter Beest G, Gisolf EH, VANB P, Waegemaekers C, Swanink C, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands. Epidemiology and infection. 2014:1–7. Epub 2014/01/09. doi: 10.1017/s0950268813003415 PMID: 24398373.

192. Saadoon I. H., Salih N. I., Saihood S. T. Hepatitis C virus infection and abortion among pregnant women in Mosul city. Medical Journal of Tikrit. 2008; 1(141):161–4.

193. Salih N. I., Saadoon I. H. Seroprevalence of hepatitis C virus among risk groups in Mosul city. Tikrit Journal of Pharmaceutical Sciences. 2007; 3(2):138–41.

194. Salman Y. G. Serological cross reaction among some causative agents of women abortions (Toxoplasma gondii & Cytomegalo virus & Rubella virus), with the incidence of hepatitis virus (B & C). Tikret Journal of Pharmaceutical Sciences. 2007; 3(2):102–11.

195. Toffik K. A., Al-Diwan J. K., Al-Hadithi T. S., Al-Waiz M. M., Omer A. R. Prevalence of the serological markers of hepatitis B, C, and D among patients with sexually transmitted diseases (STDs) in Baghdad, Iraq. Journal of the Arab Board of Medical Specializations. 2006; 8(1):105–9.

196. Al Abbadi B., Al Amr M., Abasi L., Saleem A., Abu Hazeem N., Marafi A. Seroprevalence of HBV, HCV, HIV and syphilis infections among blood donors at Blood Bank of King Hussein Medical Center: a 3 year study. Middle East Journal of Family Medicine 2014; 12(6):10–3.

197. Al-Gani FA. Prevalence of HBV, HCV, and HIV-1, 2 infections among blood donors in Prince Rashed Ben Al-Hassan Hospital in North region of Jordan. International Journal of Biological & Medical Research. 2011; 2(4):912–6.

198. Jbara I, Abu Alshiekh NK, Almomani AM, Khasawneh RH, Omari AK. Prevalence of hepatitis C virus antibodies among blood donors at Prince Hashem Hospital, Zarka- Jordan. Jordan Medical Journal. 2006; 40(3):190–3. PMID: 2007107899.

199. Irani-Hakime N, Aoun J, Khoury S, Samaha HR, Tamim H, Almawi WY. Seroprevalence of hepatitis C infection among health care personnel in Beirut, Lebanon. American journal of infection control. 2001; 29(1):20–3. Epub 2001/02/15. PMID: 11172314.

200. Ali T, Daher N. Prevalence des infections transmissibles par transfusion chez les donneurs de sang au centre de transfusion sanguine de l’universite de Damas et l’importance des mesures de la securite transfusionelle. Damascus University Journal of Health Sciences. 2010; 26(1):107–23.